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Abstract 
 
This thesis focuses on the characterization of the bioactivity, composition, molecular pathways 
and structural aspects of Chironex fleckeri venom proteins. C. fleckeri is a box jellyfish that 
recurrently causes minor to fatal envenomations on the beaches of the northern half of 
Australia. While there is an antivenom available, its effectiveness is subject to controversy and 
a rapidly acting treatment has not yet been found. One essential aspect in developing such a 
treatment is to further the current knowledge regarding the venom components and their 
effects.   
C. fleckeri venom is composed of a complex mixture of proteins which can cause rapid 
cardiovascular collapse in humans and animals. Two highly cardiotoxic, haemolytic and 
potentially pore-forming toxins have been previously identified, CfTX-1 and -2, and are 
thought to be the underlying cause for the cardiovascular collapse. Each of my chapters 
focussed on different toxinological aspects with the overall aim of shedding some light on the 
complex nature of C. fleckeri venom.  
Chapter 2 focussed on the intracellular effects of C. fleckeri venom on human cardiomyocytes. 
While the chosen method, namely fluorescence microscopy, proved inadequate for the 
intended analysis of C. fleckeri venom, the study provided some interesting results. All cells 
consistently displayed loss of adherence, nuclear condensation and loss of membrane integrity. 
The nuclear condensation, an event often observed in apoptosis, has not been previously 
reported in relation to C. fleckeri venom. 
Chapter 3 focussed on the characterisation of three previously reported bioactive fractions in 
the venom (CTF-α, CTF-β and CTF-γ). The previously reported cardiotoxic activity of CTF-α 
and CTF-β, but not CTF-γ, suggested the presence of the toxins CfTX-1 and -2 in the former 
two fractions. Interestingly, the mass spectrometric analysis revealed the presence of these 
 xi 
toxins in all three fractions, and further these toxins were most abundant in CTF-α, which in 
the present analysis displayed the least cardiotoxicity. Overall the fractions all contained CfTX-
1 and -2, CfTX-A and -B as well as three other cubozoan toxins, CqTX-1, CaTX-A and CrTX-
A, in differing proportions. This was reflected in the distinct bioactivity and activated 
molecular pathways of each of the fractions. Flow cytometry analyses revealed that neither C. 
fleckeri venom, nor CTF-α (top two hits: CfTX-1 and -2), induced apoptosis, whereas CTF-β 
(CaTX-A, CfTX-A and CfTX-B) and CTF-γ (CrTX-A and CfTX-A) treated cardiomyocytes 
were in early and late apoptotic stages, respectively. Overall, there was no apparent difference 
in bioactivity between cardiomyocytes and fibroblasts, whereas the effects of the venom on 
mouse erythrocytes was significantly higher than on human erythrocytes. This higher potency 
on mouse cells might explain why haemolysis is a symptom in laboratory animals but not in 
humans.  
Chapter 4 represents the first structural analysis of a C. fleckeri toxin. Two predicted helical 
regions of CfTX-1 were synthesised to assess experimentally whether they had helical structure 
that may have some relevance in the putatively pore-forming activity of the venom. While 
complications were encountered in aqueous solutions, both peptides formed a helical structure 
in the membrane-mimicking solvent SDS. This data represents the first experimental structural 
data in favour of a pore-forming mode of action.  
 
Overall this thesis has provided insight into the bioactivity of C. fleckeri proteins and their 
mechanisms of action, highlighted the complexity and the difficulty of working with animal 
venoms and provided some valuable insight for future studies, including those of a structural 
nature.    
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1.1. Background on the venomous box jellyfish, Chironex fleckeri 5 
 6 
Cubozoans, or box jellyfish, are a class of jellyfish that produce some of the most potent 7 
venoms in the animal kingdom [1]. While cubozoans inhabit tropical and subtropical oceans 8 
throughout the world, Chironex fleckeri, the most venomous box jellyfish [2], is found only in 9 
Australia. C. fleckeri occurs predominantly along beaches and estuaries that are located in the 10 
northern half of the Australian continent and its prevalence in shallow waters frequently leads 11 
to life-threatening human envenomations that require immediate medical attention [3].  12 
 13 
Fortunately, the annual number of deaths due to C. fleckeri is low, but the large number of 14 
minor envenomations caused by this, and related, species represents a major cost to northern 15 
Australian communities in terms of public health, leisure and tourism [3]. Particularly at risk 16 
from life-threatening C. fleckeri envenomations are children, due to their proportionally 17 
increased body exposure, and remote communities, such as the Torres Straight Islands, where 18 
C. fleckeri is found in high abundance and access to emergency services is limited. Thus far, 19 
efforts to minimise or treat the number of victims has often been based on the best available 20 
opinion rather than empirical evidence [3-5]. A box jellyfish antivenom is available, although 21 
there are controversies over its effectiveness [6]. To find an effective treatment for C. fleckeri 22 
envenomation it is crucial to expand the currently limited understanding of the mechanism of 23 
action of the venom. 24 
 25 
1.1.1. C. fleckeri envenomation 26 
C. fleckeri envenomations mostly occur in shallow beach waters during Australian summer 27 
months. Envenomations are generally the result of the accidental entanglement of bathers with 28 
the jellyfish’s tentacles. Contact with C. fleckeri tentacles triggers the rapid mechanical 29 
 3 
discharge of nematocysts (venom capsules) that inject venom into their victim via harpoon-30 
like tubules [7] (Figures 1 and 2). These nematocyst-tubules have the ability to penetrate 31 
epithelial layers and vascular walls, which enables the venom to be quickly distributed through 32 
the whole body [8]. Envenomation symptoms include instant severe pain (local, systemic and 33 
chest pain) as well as local cutaneous inflammation and necrosis [9-11].  C. fleckeri tentacles 34 
produce a distinct “frosted ladder” pattern on the skin of the victim, which can result in 35 
permanent scarring. In severe cases, victims can lose consciousness within seconds, followed 36 
by cardiovascular collapse which can result in fatal cardiac arrest less than 10 minutes post 37 
contact [10,12,13]. Other documented symptoms include arrhythmias [10,11], peripheral and 38 
coronary vasospasm, tachycardia, dilated cardiomyopathy [7,12], both rapid and weak 39 
irregular pulse and U-waves in leads I, II, aVR, aVF and chest leads V1 to V6 as well as 40 
massive pulmonary oedema with separated lung layers [12] (which indicates a cardiogenic 41 
pulmonary oedema [14]).  42 
 43 
The cardiotoxic nature of the venom has been confirmed by several in vivo studies. For 44 
example, rats suffered a transient hypertensive response followed by hypotension and 45 
cardiovascular collapse within four minutes of C. fleckeri venom administration (0.03 μg/g) 46 
[15]. Similarly, after an initial increase in mean arterial pressure, partially purified C. fleckeri 47 
venom (0.025 μg/g) induced cardiovascular collapse in mice within one minute of 48 
administration [16]. However, the molecular mechanisms underlying the cardiovascular 49 
collapse remain largely unknown. 50 
 51 
 4 
 52 
Figure 1: Simplified diagram of an (A) intact and (B) discharged C. fleckeri nematocyst.  53 
 54 
Figure 2: Sequence shots of a live nematocyst discharge time-lapse. The time point of each picture is indicated in 55 
the bottom right corner of each image. The dark green area represents the live tentacle (T) and the ejecting 56 
nematocysts tubules are indicated by the red arrows and brackets (NT). This image was created from Copyright 57 
material of BIOPIXEL.  58 
 59 
1.1.2. Treatment for C. fleckeri envenomation  60 
 61 
No generally effective treatment for C. fleckeri envenomation exists. The current first aid 62 
guidelines released by the Australian Resuscitation Council are summarized in Figure 3. 63 
Vinegar, as mentioned in the guidelines, is present at most tropical beaches and used as the 64 
primary local treatment for C. fleckeri (and other tropical jellyfish) stings. Vinegar prevents 65 
 5 
venom capsules that have not been discharged, from doing so [17]. However, like other 66 
previously applied treatments (e.g. pressure immobilisation bandages [4,18] and ice packs 67 
[19]), there is no empirical evidence to show that vinegar is safe to use for box jellyfish 68 
envenomation. On the contrary, it was shown recently that venom capsules that have already 69 
discharged still retain about 40 % of venom within the capsule and, upon vinegar application, 70 
the remaining venom is released, and therefore has the potential to do harm when used as a 71 
treatment [5].  72 
 73 
C. fleckeri antivenom is carried on board 74 
Queensland emergency service vehicles. 75 
The antivenom is produced by the 76 
Commonwealth Serum Laboratories (CSL) 77 
in Melbourne from the erythrocytes of sheep 78 
treated with C. fleckeri venom. As 79 
mentioned above, evidence on the 80 
effectiveness of the CSL-antivenom is 81 
controversial. Antivenom is only effective if 82 
given prophylactically [20,21], resulting in 83 
difficulties when designing clinically 84 
relevant in vivo studies. For example, venom injected into chick biventer nerve-muscle 85 
preparations reduced the twitch height of the preparation. Antivenom administered after 86 
envenoming had no effect on venom-induced reduction in twitch height, whereas prophylactic 87 
administration of antivenom (10 minutes prior to venom administration) resulted in significant 88 
attenuation of the effect of the venom. Similarly, venom-induced inhibition of cell proliferation 89 
was prevented in A7r5 cells preincubated with antivenom (5 U/mL), in contrast to post-venom 90 
Current ARC first aid guidelines in tropical* 
Australia 
 
• Remove victim from water, restrain if 
necessary 
• If victim looks/feels unwell seek medical 
assistance (000 and lifeguard) 
• Commence CPR if victim stops breathing 
• Douse sting area with vinegar (30 seconds) 
and remove remaining tentacles  
• If vinegar is inaccessible, remove 
tentacles, then rinse with seawater 
• Do not pour freshwater over sting  
 
* In the non-tropical parts of Australia, the sting 
may be caused by the ‘Blue-bottle’ and vinegar is 
not recommended as it may cause further firing of 
‘Blue-bottle’-nematocysts. 
Figure 3. Summary of first aid guidelines for C. fleckeri 
envenomation as suggested by the Australian 
Resuscitation Council (ARC) (https://resus.org.au/ 
guidelines) 
 6 
antivenom administration [22]. However, in vivo, even prophylactic antivenom administration 91 
resulted in only 40 % survival in C. fleckeri envenomed (0.2 μg/g) rats as opposed to 0 % 92 
survival for the control group (no antivenom) [15]. In combination with magnesium sulphate, 93 
prophylactic antivenom administration resulted in 100 % survival of envenomed (0.03 μg/g) 94 
rats [15]. These results show that the antivenom can mitigate the venoms effects to some extent, 95 
but prophylactic administration is not in accordance with a clinically relevant setting. 96 
 97 
In general, there are logistical problems with C. fleckeri antivenom in terms of timely dose, 98 
administration, and production. For instance, lack of knowledge of the amount of venom 99 
injected into a victim during an envenomation can prevent an accurate dose from being 100 
administered. In the case of a severe envenomation, cardiovascular collapse may occur before 101 
emergency services arrive at the scene. Additionally, antivenom is often given intra-muscularly 102 
[7]. Yet, the harpoon-like tubule from C. fleckeri nematocysts has the ability to penetrate 103 
epithelial layers and vascular walls; i.e. the venom is transported through the vascular system 104 
[8]. Therefore, intramuscular injection of antivenom at the sting site may be appropriate for 105 
local tissue damage; however, whether it is the right approach for neutralising the venom 106 
already in the vascular system, is debatable. Additionally, a recent study has shown that the 107 
effects of C. fleckeri antivenom are both dose and time dependent. Prophylactic doses of 108 
antivenom required 70 minutes to unfold their full effect in vitro and the doses required were 109 
approximately five times the currently recommended initial dose (max. 3 vials, i.e. 3 x 20’000 110 
units) [23]. Furthermore, the variability of the effectiveness of the antivenom may be related 111 
to the geographical [22] and ontogenetic [24] differences in the venom from individual C. 112 
fleckeri specimens, i.e. the venom used for antivenom production may not be as potent as the 113 
venom from other C. fleckeri individuals. While some of these logistical problems can be 114 
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addressed (e.g. doses and intravenous administration), the timely arrival of emergency services 115 
is circumstantial, and the venom used for antivenom production is contingent to availability.  116 
 117 
In conclusion, alternative treatments that block the key molecular pathways in the 118 
envenomation process may be required instead of, or in combination with, C. fleckeri 119 
antivenom. Also, given the circumstances, any treatment for severe C. fleckeri envenomation 120 
would ideally be accessible at the beach and unfold its full effects rapidly in a systemic manner.  121 
 122 
1.1.3. C. fleckeri venom proteins 123 
 124 
The characterisation of C. fleckeri venom proteins has been a challenge in terms of specimen 125 
collection, venom extraction and biochemical properties of the venom proteins. The protein 126 
composition and the potency of the venom vary depending on the size of the animal [24] as 127 
well as the geographical location and the year that a specimen is collected [22]. Venom from 128 
specimens collected in Weipa, NT showed a different protein composition on a 12 % SDS-129 
page gel than venom collected from specimens in Broome, WA or Mission Beach, QLD [22]. 130 
This variation in protein composition was reflected in the activity of the venom, with venom 131 
from Weipa eliciting more potent toxicity in cells as well as distinct and more pronounced 132 
effects on the cardiovascular system of anesthetised rats than venom from Broome. Further, 133 
differences in venom composition were found between juvenile and adult C. fleckeri 134 
specimens, which correlated with an ontogenetic shift in dietary preference of the animals [24].   135 
 136 
The extraction method used for analysis of C. fleckeri venom can also impact the proteins 137 
present in the samples. Early studies used tentacle extracts [e.g. 25,26] but an 12 %-SDS-Page 138 
gel comparison revealed that venom free of tentacular material has a different protein 139 
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composition than that found in the tentacles [27]. Tentacles are not injected in the 140 
envenomation victim, making analysis of venom free of tentacular debris more likely to be 141 
clinically relevant. In addition to inconsistent extraction methods, the venom proteins in C. 142 
fleckeri venom have been reported to have a tendency to aggregate and adhere to surfaces 143 
[26,28,29], making purification difficult. Further, primary sequence and SDS-PAGE analysis 144 
indicated some of the C. fleckeri venom proteins are glycosylated which can complicate 145 
analysis of the proteins, particularly with mass spectrometry [31|. 146 
 147 
Despite the challenges in isolating C. fleckeri proteins, the recent consensus to work with C. 148 
fleckeri nematocyst derived venom has led to the characterisation of several proteins that 149 
belong to a family of potent toxins that are unique to cnidarians [16,32,33]. This family of 150 
cnidarian venom toxins exhibit several biological activities including cardiotoxicity, pore-151 
formation, cytolysis, dermonecrosis and haemolysis [1,33,34]. Following a phylogenetic 152 
analysis these toxins have been divided into Type I and Type II toxins [16]. Both toxin types 153 
contain signal peptides, with the distinction that Type II toxins also generally contain an N-154 
terminal pro-region, which is typically a significant modulator in biosynthesis and activation 155 
(e.g. transport, correct folding, post-translational modifications, etc.) [16]. Further, mature 156 
Type II toxins tend to be shorter in sequence length (thus generally lower in molecular weight) 157 
than Type I toxins. Despite these distinct characteristics, both toxin types have been predicted 158 
to have similar secondary and tertiary structures [16]. Also, these cubozoan toxins are likely to 159 
form dual-domain mature proteins, with a tendency to oligomerize to form large heterogenous 160 
Type I or Type II holotoxins [16].  161 
   162 
Thus far, the full cDNA sequences of five C. fleckeri venom proteins (CfTX-1, CfTX-2, CfTX-163 
A, CfTX-B and CfTX-Bt – protein sequence determined by Edman degradation) have been 164 
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identified and cloned [16,32]. CfTX-1 and -2 were classified as Type I toxins and CfTX-A, -B 165 
and -Bt as Type II toxins (Figure 4). Mature CfTX -1 and -2 are 436-residue and 445-residue 166 
proteins, respectively, with calculated molecular masses of 49,146 and 49,883 Da, respectively 167 
and estimated isoelectric points (pI) of 8.3 and 7.3 respectively [32]. Mature CfTX-A and -B 168 
are 429- and 430-residue proteins respectively with theoretical masses of 47,577 (pI 6.3) and 169 
47,655 Da (pI 7.1), respectively [16]. A lower abundance C-terminal truncated form of CfTX-170 
B was also cloned (CfTX-Bt; 296 residues; mol. weight: 31,293 Da; pI: 5.2) as a result of two 171 
distinctly identified cDNA populations encoding mature CfTX-B. Although the CfTX-Bt 172 
transcript was not found during the transcriptome assembly, a truncated form of CfTX-1 173 
containing a signal sequence and a domain similar to the N-terminal domain was identified 174 
[35].  175 
 176 
Figure 4: Simplified toxin phylogram as classified into Type I and Type II toxins by [16]. The toxin name is 177 
followed by the species name. All species belong to the class Cubozoa, except for Aurelia aurita (Scyphozoa) and 178 
Hydra magnipapillata (Hydrozoa). 179 
Secondary structure prediction indicates that the first 300 N-terminal amino acids of all above-180 
mentioned CfTXs are dominated by α-helices and loop regions, whereas the rest of the 181 
sequences were predicted to be dominated by β-sheets and loop structures [16,32]. For CfTX-182 
1 and -2 an amphiphilic α-helix as well as a transmembrane spanning region were also 183 
TX-2, Aurelia aurita 
CqTX-A-like, Hydra magnipapillata  
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predicted in the N-terminal region. Because these structures are common in pore-forming 184 
toxins [36] and the predicted transmembrane spanning regions consist of a series of conserved 185 
amino acids (also found in CqTX-A from Chiropsalmus yamagucchii, in CaTX-A from Alatina 186 
alata and in CrTX-A and -B from Carybdea rastoni), pore-formation has been suggested as a 187 
potential common property of these cubozoan toxins [32]. Additionally, tertiary structure 188 
prediction of CfTX-A and -B suggests structural homology to pore-forming Bacillus 189 
thuringiensis three domain Cry-toxins (Crystal proteins [36]) [16]. Currently, no experimental 190 
structural data exists on full-length C. fleckeri venom proteins. 191 
 192 
Analysis of the C. fleckeri transcriptome has indicated that the venom composition is quite 193 
diverse, with more than 170 potential toxin proteins. Seven of these potential toxins have 194 
sequence similarity to the previously characterised CfTX proteins and have subsequently been 195 
identified using tandem mass spectrometry [30]. Other putative toxins were identified 196 
including metalloproteinases, an α-macroglobulin domain containing protein, peroxiredoxin 197 
toxins, CRISP proteins, a turripeptide-like protease inhibitor as well as other proteases [35]. 198 
However, with only one transcriptome analysis conducted so far, and the lack of genome data, 199 
the current C. fleckeri venom proteome data is likely to be incomplete.  200 
 201 
1.1.4. Mechanism of action of C. fleckeri venom 202 
 203 
The mechanism of action of C. fleckeri venom is poorly understood, but insights have been 204 
gained by analysis of crude venom (i.e. the whole complex mixture of biomolecules from the 205 
nematocysts) or partially purified venom fractions from chromatographic techniques 206 
[6,20,27,37]. Based on the rise in calcium levels upon C. fleckeri venom treatment, an 207 
interference with transmembranic calcium channels was initially suggested [13]. Analysis of 208 
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the calcium channel blocker verapamil was controversial due to opposing results from different 209 
research papers [13, 40]. Another study testing calcium (nifedipine, Ni2+) and sodium 210 
(tetrodotoxin, strophanthidin, amilorides) channel blockers, as well as inhibitors of the 211 
sarcoplasmic reticulum (ryanodine), suggested that a rise in sodium due to a non-specific cation 212 
leakage through the cell membrane induced an excessive influx of calcium into the heart cell 213 
[38]. Electron microscopic analysis indicated that the venom has pore-forming properties [39], 214 
consistent with the ion influx into the cell [38]. It has been suggested that this spontaneous and 215 
excessive Na+-mediated influx of Ca+ in cardiomyocytes triggers irregular contractions of the 216 
single cell, resulting in an overall asynchrony and flagging in communal heart cell contractions, 217 
thus causing arrhythmias leading to eventual cardiac failure [38].  218 
 219 
Another hypothesis, suggesting that the envenomation symptoms originate from a 220 
hyperadrenergic reaction, was refuted when a C. fleckeri venom induced an irreversible 221 
contractile response on rat aortas despite prazosin treatment, an α1-adrenoreceptor antagonist 222 
[6]. Further, venom induced hypertension and cardiovascular collapse in anaesthetized rats 223 
could not be prevented by prasozin or ketanserin, a serotonin 5HT-receptor antagonist [27]. 224 
Thus, an α1-adrenoreceptor mediated hyperadrenergic response to C. fleckeri venom is 225 
unlikely [6,27] and consequently, it appears likely that pore-formation is a key factor in the 226 
venom induced cardiovascular collapse.  227 
 228 
Based on the structural predictions of the CfTX-toxins it appears likely that these toxins are 229 
responsible for the pores observed by electron microscopy [39], but this has yet to be 230 
confirmed. For instance, other proteins are present in the crude venom, which could be 231 
responsible for pore formation.  Additionally, it is unknown what role and consequences the 232 
pore formation has in terms of cell death; i.e. do the pores lead to cell death? Which type of 233 
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cell death? These questions, as well as how the proteins potentially insert themselves into the 234 
cell membrane, remain unanswered and need to be addressed.  235 
 236 
1.2. Aims and significance  237 
 238 
The present research project addressed C. fleckeri venom research gaps in terms of bioactivity, 239 
cellular death pathways and experimental structural analysis. Chapter 2 aimed to visualise the 240 
effect of C. fleckeri venom on the cardiomyocyte by using fluorescence microscopy. Chapter 241 
3 aimed to characterise 3 bioactive venom fractions, two of which are known to be cardiotoxic, 242 
as well as a third fraction for comparison, in order to shed more clarity on the cardiotoxic 243 
mechanisms of the venom. Finally, Chapter 4 aimed to conduct an experimental structural 244 
analysis of two helical regions of the cardiotoxic and hemolytic C. fleckeri venom protein 245 
CfTX-1. The outcomes provide some clarity on how the venom and its toxins affect different 246 
cell types, in particular the cardiomyocyte, and potential mechanisms involved in cell death. 247 
Moreover, this project presents the first structural analysis of a C. fleckeri venom toxin, which 248 
is expected to provide a baseline for future structural studies on C. fleckeri venom toxins. 249 
 250 
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CHAPTER 2 349 
Fluorescence microscopy imaging and flow 350 
cytometry analyses of C. fleckeri venom effects 351 
on cardiomyocytes 352 
 17 
2.1. Introduction 353 
 354 
The rapid cardiovascular collapse observed in severe C. fleckeri envenomations has led to 355 
research focus on cardiovascular effects of the venom. In their attempts to understand these 356 
venom-induced cardiovascular effects on a systemic level, most research was conducted on 357 
live animals and animal tissue.  358 
 359 
The in vivo and animal tissue studies have predominantly provided insight into the physiology 360 
of C. fleckeri induced cardiovascular symptoms as well as on the effectiveness of potential 361 
treatments. For example, C. fleckeri venom (0.5-30 μg/kg) caused a transient increase in mean 362 
arterial blood pressure followed by cardiovascular collapse within minutes in anaesthetised rats 363 
[1-4]. Due to this rise in arterial blood pressure, several blood pressure drugs were tested in 364 
combination with antivenom for their capacity to prevent cardiovascular collapse.  Antivenom 365 
combined with magnesium sulphate prevented cardiovascular collapse only when pre-366 
administered but could not attenuate the transient pressure response [2]. Neither the transient 367 
pressure response nor the cardiovascular collapse could be mitigated by antivenom or 368 
magnesium sulphate alone, verapamil [2], prazosin or ketanserin [1]. Also, C. fleckeri venom 369 
caused contractions in rat-isolated small mesenteric arteries, biphasic left atrial responses and 370 
decrease in right atrial rate followed by atrial standstill [4]. The effects on the arteries could 371 
not be attenuated by arterial blood pressure medications (prazosin, bosentan, calcitonin gene-372 
related peptide (CGRP8-37) or tetrodotoxin) and the effect on the atria could not be prevented 373 
by propranolol, atropine or CGRP8-37, however atrial standstill was prevented by pre-treatment 374 
with C. fleckeri antivenom [4]. These results suggested that C. fleckeri venom acts directly on 375 
the cardiac muscle and not via sympathetic nervous system pathways [1,4]. Further, it remains 376 
questionable whether C. fleckeri antivenom has the capacity to be effective in a clinically 377 
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relevant setting (i.e. administration at least 10 minutes post-envenomation) [reviewed in 5] and 378 
therefore research has shifted towards understanding the mechanism of action of C. fleckeri 379 
venom on a cellular level.   380 
 381 
The studies on the effect of C. fleckeri venom on cell lines are limited, with less than ten 382 
published studies, of which only four used human cardiomyocytes [6-9]. These studies on 383 
cardiac cell lines have primarily analysed the cytotoxicity of the venom or partially purified 384 
fractions. For example, C. fleckeri venom was found to be more toxic to cardiac cells than to 385 
skeletal muscle cells, and to act in a dose-dependent manner [6,9]. A subsequent study 386 
involving fractionation of the venom using size-exclusion chromatography, found that only 387 
peak two of the resulting A280 absorbance trace, appeared to be cardiotoxic [7]. Within this 388 
peak, fractions termed CTF-α and -β, were primarily responsible for the observed toxicity on 389 
human cardiomyocytes, with IC50 concentrations after ten minutes exposure to venom of 390 
approximately 0.25 μg/mL and 0.6 μg/mL, respectively [8]. The proteins present in these 391 
fractions were not determined. While these studies have provided insight into the properties 392 
and potency of the venom, none of them focussed on the intracellular effects. 393 
 394 
Only one in vitro study has analysed C. fleckeri venom with a focus on its intracellular 395 
cardiotoxic effects. Ventricular rat and ferret myocytes were isolated and analysed post venom 396 
exposure with an electrophysiological approach, identifying non-specific ion leakage into the 397 
cell, with sodium-mediated spikes of intracellular calcium levels, and thus leading to the 398 
suggestion that C. fleckeri venom forms pores in cells [10]. However, this study used crushed 399 
tentacle extracts and thus it is not clear whether the observed effects on the cells stem from the 400 
tentacles, which are known to be cardiotoxic [1], or the venom itself. 401 
 402 
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As a result of the limited number of studies, very little is known about how C. fleckeri venom 403 
affects human cardiac cells or the organelles within the cell. Cell survival is related to the 404 
proper functioning of its organelles such as the nucleus and the mitochondria. Altered 405 
morphology of the nucleus has been implicated in different types of cell death [11] and some 406 
unpublished data exists that suggest that C. fleckeri venom reduces of the cellular nucleus (pers. 407 
communication Dr. Smout). Likewise, mitochondria are of particular importance to the 408 
functioning of the cardiomyocyte; heart muscle is a highly oxidative tissue; more than 90 % of 409 
the energy for cardiomyocytes comes from mitochondrial respiration [12]. Mitochondria are 410 
also involved in calcium cycling [13], which in turn is a key factor in the mechanism of the 411 
cardiomyocyte contraction. As such, altered mitochondrial function has been implicated in 412 
cardiac dysfunction and heart failure [14], for example, right ventricular failure is associated 413 
with increased mitochondrial activity [15]. Analysis of the effects of C. fleckeri venom on these 414 
organelles might direct future research into the mode of action of the venom.  415 
 416 
This chapter assesses the effects of C. fleckeri venom on a variety of heart cellular organelles 417 
and the integrity of the cell membrane to provide a detailed analysis of the toxicity-induced 418 
damage to cardiomyocytes. Fluorescence microscopy and flow cytometry were used to provide 419 
a qualitative and quantitative analysis, respectively, of C. fleckeri venom on the heart cell and 420 
its organelles.  421 
  422 
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2.2. Methods 423 
 424 
2.2.1. C. fleckeri venom collection and extraction  425 
 426 
C. fleckeri specimens were collected for their venom from Weipa (12.6493° S, 141.8470° E) 427 
in March 2015. Nematocyst collection followed the method of Bloom et al., 1998 [16]. In brief, 428 
tentacles were removed from the specimens and placed into containers with ocean water at 4 429 
ºC for 3 days. The containers were lightly shaken several times a day to promote autolysis of 430 
the nematocysts from the tentacles. On the third day, the solution was run through a fine wire 431 
mesh sieve to remove the tentacles and other large debris. The nematocyst solution was then 432 
lyophilised for 48 h and stored at -80 ºC until required for venom extraction.  433 
 434 
Venom extraction followed the method of Carrette and Seymour, 2004 [17]. In short, 435 
approximately 5 μg of lyophilised nematocysts were put into 3 mL vials with approximately 436 
0.5 mL of glass-beads and filled with Milli-Q-water (MQ) (at 4 °C). The mixture was shaken 437 
at 5,000 rpm in a Mini-BeadBeater-16 (Glen Mills, Inc., USA) 10 times for 2 min to maximise 438 
nematocyst rupture and venom yield. After each time in the beater the vials were cooled in ice 439 
slurry for 5 min. The mixture was then centrifuged for 45 s at 20 000 g. Finally, the supernatant 440 
(i.e. soluble venom proteins) was collected and subsequently lyophilised. The lyophilised 441 
venom was stored at -80 °C until required for use.  442 
 443 
2.2.2. Cell culture 444 
 445 
Human cardiomyocytes (ScienCell Research Laboratories, Inc., USA) were cultured following 446 
the manufacturers guideline in 5 mL Cardiac Myocyte Medium (ScienCell Research 447 
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Laboratories, Inc., USA), at 37 °C and 5 % CO2 in T25 monolayer flasks. Cells were allowed 448 
to grow to 60 % confluence before they were split. At 60 % confluence, cells were washed in 449 
3 mL Dulbecco’s phosphate buffered saline (PBS; Thermo Fisher Scientific, Inc., USA) and 450 
then detached by incubating for 3 minutes at 37 °C and 5 % CO2 with 1 mL TrypLE (Thermo 451 
Fisher Scientific, Inc., USA). The detached cells were then suspended in 5 mL of media, 452 
centrifuged at 37 ºC, 150 g and the supernatant TrypLE/media solution was discarded. The cell 453 
pellet was resuspended in 5 mL of media and introduced into new T25 flasks at approximately 454 
5 % confluence. Cell splitting was conducted at least 4 times to ensure adequate viability of 455 
the cells before initiating the experiments.  456 
 457 
2.2.3. Fluorescence microscopy 458 
 459 
2.2.3.1. Cell transfer into chamber slides 460 
 461 
The cardiac cells were transferred into 8-well chamber 462 
slides (NuncTM Lab-TekTM II Chamber SlideTM System, 463 
Thermo Fisher Scientific, Inc., USA; Figure 1) using the 464 
same procedure as for cell splitting. After addition of the 465 
cells, each well, i.e. chamber, was filled with 500 μL media. 466 
The chamber slides are equipped with a lid, allowing for cell 467 
incubation in similar conditions to tissue culture flasks. 468 
Further, the chambers are removable, turning the chamber 469 
slide system into a standard slide for microscopic analysis.   470 
 471 
 472 
 473 
Figure 1: Lab-TekTM II Chamber SlideTM 
System with 8 removable chambers and lid 
for incubation.  
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2.2.3.2 Optimising cell incubation and confluence in the chamber slides 474 
 475 
To identify the shortest incubation period necessary for adequate cell adherence in the chamber 476 
slides, the cells were incubated for 24, 48 and 72 h. After the incubation, the cells were visually 477 
inspected under a brightfield microscope, then washed and inspected again. Washing entails 478 
the removal of old media, addition and subsequent removal of 0.3 mL of PBS (i.e. washing), 479 
and re-addition of 0.5 mL of fresh media.  480 
To optimise cell confluence for the experiments; the chamber slides were incubated with 481 
concentrations 10,000, 20,000, 30,000, 40,000, 50,000 and 60,000 cells/mL and subsequently 482 
inspected under a brightfield microscope. 483 
 484 
2.2.3.3. Optimising the staining procedure 485 
 486 
Note: Due to the lack of literature for this staining procedure with the use of C. fleckeri venom, 487 
each step of this method was visually inspected under the brightfield microscope to ensure cells 488 
were still adhering to the slide surface or whether a step required optimising. 489 
Following incubation, old media was removed, cells were washed (washing = addition and 490 
immediate removal of a solution) in 300 μL PBS (37 ºC) to remove debris and dead (floating) 491 
cells and new media (490 μL, 37 ºC) was added. Following the manufacturers guidelines, 10 492 
μL of dye were added to the solution (total volume 500 μL) for 10 min, followed by another 493 
washing step in 300 μL PBS (37 ºC) and new media addition (480 μL, 37 ºC). The venom (20 494 
μL) was added to the cell-media solution and allowed to incubate for 10 min (total volume 500 495 
μL).  496 
 For the optimisation of the staining procedure, initially an in-well venom concentration of 10 497 
μg/mL was used, as this is approximately the venom concentration that kills 50 % of the cells 498 
(IC50) after 10 min in an xCELLigence real-time assay [7] (In 2.2.3.4. a venom concentration 499 
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more suited for the fluorescence imaging is determined). The venom-media solution was then 500 
decanted, and the chambers were removed.   501 
For each dye three replicates, i.e. three chamber slides, were used. Of the eight chambers on 502 
each slide, four were used as control (480 μL of media + 20 μL MQ-water) and four were used 503 
for the venom (480 μL of media + 20 μL venom).  504 
 505 
2.2.3.4. Venom concentration 506 
 507 
The venom concentration was determined via Bradford assay. Seven tenfold dilutions of 285 508 
μg/mL were conducted (lowest concentration: 0.285 ng/mL) and then added to the chambers. 509 
One chamber slide per concentration was used. On each chamber slide, four chambers were 510 
used for the venom and four were used for the Milli-Q-water-control (MQ-control), following 511 
the procedure described in (2.3.). The nuclear stain Hoechst 33342 (InvitrogenTM, USA; see 512 
2.2.3.5.1), a common user-friendly nuclear stain, was used to permit for visual inspection of 513 
the results under the fluorescence microscope.  514 
 515 
2.2.3.5. Fluorescent imaging of the envenomed cardiomyocyte  516 
 517 
Three aspects of the effects of C. fleckeri venom on the cardiomyocyte morphology were 518 
analysed:  519 
 520 
2.2.3.5.1 Nuclear morphology 521 
 522 
To visualise the effects of C. fleckeri venom on the nuclear morphology of cardiomyocytes, 523 
cells were incubated for 10 min with 5 μg/mL of the nuclear stain Hoechst 33342 524 
(InvitrogenTM, USA). Hoechst 33342 binds into the minor groove of DNA, preferentially to 525 
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adenine-thymine (A-T) regions (InvitrogenTM, USA). This stain exhibits distinct fluorescence 526 
emission spectra that are dependent on dye:base pair ratios (InvitrogenTM, USA). 527 
 528 
2.2.3.5.2. Cell membrane integrity 529 
 530 
Two stains were used for the assessment of the cell membrane integrity, Propidium Iodide 531 
(InvitrogenTM, USA) and CellMaskTM Deep Red (InvitrogenTM, USA). Propidium Iodide (PI) 532 
is a non-permeant nuclear counter stain that is usually used in combination with a cell permeant 533 
dye like Hoechst 33342 to analyse the integrity of cell membranes. Intact healthy cells exclude 534 
PI, whereas cells with damaged cell membranes are stained brightly red. Cells were incubated 535 
for 10 min with in-well concentrations of 5 μM and 5 μg/mL of PI and Hoechst 33342, 536 
respectively. CellMaskTM Deep Red is a plasma membrane stain that allows for the 537 
visualisation of the entire cell under the fluorescence microscope. Cells were incubated for 10 538 
min with an in-well concentration of 5 μg/mL CellMask Deep Red [18].  539 
 540 
2.2.3.5.3. Mitochondrial activity 541 
 542 
To assess mitochondrial activity, cardiomyocytes were incubated with for 10 min with 100 nM 543 
MitoTrackerTM Deep Red FM (InvitrogenTM, USA). MitoTracker is a mitochondrion selective 544 
stain that is concentrated by active mitochondria. The more active the mitochondria are, the 545 
higher the intensity of the Mitotracker stain will be [19]. 546 
 547 
2.2.4. Flow cytometry 548 
 549 
The cells were split and then counted to prepare 200 μL solutions of 500 000 cells/mL. For the 550 
first experiment, cells were incubated for 2, 10 and 30 minutes with 3 different venom 551 
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concentrations (80 ng/ mL, 8 ng/ mL and 0.8 ng/ mL) to determine a venom concentration and 552 
incubation period that would allow for a decrease and increase (left- and rightwards shift, 553 
respectively, on generated graphs) of the fluorescent signal intensity. Following incubation, the 554 
cells were centrifuged at 150 g, at room temperature for 5 min, then the supernatant was 555 
removed, and the cell pellet was resuspended in 0.2 mL media. The cells were then incubated 556 
with propidium iodide for 10 min at a 5 μM.  557 
 558 
All following experiments were prepared in the same manner, i.e. with the above chosen venom 559 
concentration and with the corresponding dyes. Dye incubation times and concentrations for 560 
Hoechst and MitoTrackerTM Deep Red FM were 5 μg/mL for 10 minutes and 100 nM for 30 561 
minutes, respectively, according to the manufacturer’s guidelines. Following incubation with 562 
the dye, the cells were centrifuged again at 37 °C, 150 g for 5 min and resuspended in 200 μL 563 
of fresh media.  564 
The cells were loaded onto a BD FACSCantoTM II flow cytometer (BD Biosciences) with the 565 
BD FACSDivaTM software (BD Biosciences). For each sample, 10,000 cells were counted and 566 
analysed. Fluorescence was measured in the FITC, Pacific Blue and PerCP-Cy5-5 channels 567 
with excitation and emission wavelengths as follows:  Propidium Iodide (493/636 nm), 568 
Hoechst (361⁄497), MitoTrackerTM Deep Red FM (581/644 nm). Statistical analysis was 569 
carried out in GraphPad Prism 7.0; the data was tested for normality and then analysed via 570 
One-way ANOVA with a Dunnett’s multiple comparison test.  571 
 572 
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2.3. Results  573 
 574 
To analyse the effects of the venom on cardiomyocytes a range of organelle specific fluorescent 575 
dyes were used. However, before these experiments could be carried out several parameters 576 
were assessed to guide the design of the staining experiments. These parameters included 577 
analysis of cell adherence to the chamber slides, incubation time of the cells with venom, the 578 
number of wash steps required to remove dead cells, dye or venom solution. Furthermore, the 579 
optimal venom concentration had to be identified, i.e. a concentration that would allow 580 
visualisation of the effects on the cells without a large percentage of cell death, or cells 581 
detaching from the surface of the chamber slides. 582 
 583 
2.3.1. Fluorescence microscopy 584 
 585 
2.3.1.1. Cell attachment, incubation time and cell confluence  586 
 587 
Cell adherence, incubation time and cell confluence were assessed to ensure the cells were 588 
evenly spread across the wells and would not detach due to mechanical disturbances such as 589 
media or treatment addition or removal. Even distribution of the cells is also important for 590 
imaging purposes in order to facilitate focussed imaging and allow for systematic analysis.  591 
 592 
Cardiomyocyte adherence to Lab-Tek® II Chamber slides was tested by incubating 30,000 593 
cells/mL in 500 μL of cardiomyocyte medium for 24, 48 and 72 hours at 37ºC and 5 % CO2. 594 
Visual inspection of the wells under a brightfield microscope showed that the cells were not 595 
adhering even after the longest incubation period of 72 hours (not shown). The experiment was 596 
repeated with Lab-Tek® II – CC2TM Chamber SlideTM System slides with a specialised CC2 597 
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coating for fastidious cells. Visual inspection showed that the cells were adhering well for all 598 
incubation periods, and subsequent experiments were carried out with these slides. However, 599 
when the cells were washed to test if they were still adhering after physical disturbances (i.e. 600 
adding and removing new media etc), cells incubated for less than 72 hours resulted in more 601 
than approximately 20 % cell detachment.  602 
 603 
Using the Lab-Tek® II – CC2TM Chamber Slides the influence of cell confluence on 604 
photographic imaging was tested by incubating the chambers with a range of cell numbers 605 
(10,000, 20,000, 30,000, 40,000, 50,000 and 60,000 cell/mL) in 500 μL of media for 72 hours 606 
at 37ºC and 5 % CO2. 20,000 cells/mL resulted in approximately 80 % confluence, which is 607 
recommended by the cell line manufacturer for ideal viability, whereas 30,000 cells/mL or 608 
more resulted in 100 % confluence and thus cell clustering, leading to difficulties in achieving 609 
adequate focus with the camera (Figure 2). Using 10,000 cells/mL was adequate for the purpose 610 
of imaging but resulted in only approximately 50 % confluence (Figure 2). Consequently, the 611 
concentration of 20,000 cells/mL incubated for 72h was used for all further experiments. 612 
 613 
Figure 2: Brightfield images of different cell concentrations incubated for 72 h in Lab-Tek® ii-CC2TM Chamber 614 
SlideTM System (8-well chamber slides; 0.5mL/well). Cells with 30,000 cells/mL or greater resulted in overgrowth 615 
and clustering of the cells (see dark patches circled in red) making them unsuitable for systematic imaging. 20,000 616 
cells/mL were chosen as the most suitable conditions for the following experiments.   617 
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2.3.1.2. Development of the staining procedure 618 
 619 
The chamber slide system is a method for the analysis of fixed cells, but the aim of the current 620 
experiments was to study the effects of the venom on live cells, and therefore the 621 
manufacturer’s protocol had to be modified. The protocol recommended in the Lab-Tek® II – 622 
CC2TM Chamber Slides protocol (without the fixation step), involves the following steps: 1) 623 
cell wash, 2) dye addition, 3) cell wash, 4) treatment addition (i.e. venom), 5) chamber removal. 624 
Because the original application of the slides differs from the current experiment, each step 625 
was evaluated by visual inspection and adjusted (if necessary), as outlined below: 626 
 627 
1) Wash  628 
To remove dead or unhealthy cells (i.e. floating cells) from the chambers, old media 629 
was decanted, the cells were washed in 300 μL pre-warmed (37ºC) PBS (with 630 
subsequent removal of the PBS) and then 490 μL of new pre-warmed (37ºC) media was 631 
added. However, based on visual inspection this procedure resulted in the cells 632 
detaching from the bottom of the chamber slides. Replacing the PBS with media 633 
resulted in only approximately 20 % cell detachment. A further improvement was 634 
obtained when the media was applied very slowly and resulted in only approximately 635 
5 % detachment of the cells. 636 
 637 
2) Dye addition 638 
Initial experiments were carried out using the nuclear stain Hoechst 33342 as it has a 639 
simple staining protocol. Following the manufacturer’s guidelines, cells were incubated 640 
in the cell-media solution (490 μL) with 10 μL of dye for 10 minutes at 37 ºC (total 641 
volume 500 μL). Visual inspection did not reveal any cell detachment, suggesting this 642 
stain was appropriate to use.  643 
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3) Wash 644 
To remove excess dye, another wash step was conducted with media (added gently) 645 
instead of PBS as described in step 1) of the experimental procedure. After the wash, 646 
480 μL of new, pre-warmed media was added. Visual inspection indicated minor cell 647 
detachment with approximately 5 % of the cells floating in the fresh media solution, 648 
which was deemed acceptable for the experiment and consequently the effects of the 649 
venom were analysed. 650 
 651 
4) Addition of venom and MQ-water control  652 
The venom concentration initially chosen was 10 μg/mL, as this concentration has 653 
previously been shown to cause approximately 50 % cell death after 10 minutes when 654 
added to wells loaded with 3000 cells and incubated for 12 hours [7]. The venom 655 
concentration was optimised in a separate experiment, after the experimental procedure 656 
was established (See section 2.3.2.1). 20 μL of venom and 20 μL of MQ-water control 657 
were added to four chambers each and incubated for 10 minutes at 37ºC. Following 658 
incubation, the venom/media solution was removed. Visual inspection was carried out 659 
after chamber removal (see step 5). 660 
 661 
5) Chamber removal 662 
The chambers were removed following the manufacturers guidelines. Visual inspection 663 
after chamber removal revealed that the venom had leaked from adjacent chambers into 664 
the control chambers. This was identified by the presence of nematocysts and cell 665 
detachment in the control wells (i.e. wells without venom) (see Figure 3). This presence 666 
of nematocysts revealed two problems with the experiment. Firstly, it suggested that 667 
the venom used here was not free from larger debris; therefore, an additional filtration 668 
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step with a 45 μm filter was included in the venom extraction method used to remove 669 
any macromolecular debris, i.e. unruptured nematocysts from the venom. Secondly, 670 
there should not have been any leakage from one well across another, i.e. venom should 671 
not leak into control wells, which indicated that an additional wash was required after 672 
the venom addition and before the chamber removal. However, adding another wash to 673 
the staining procedure would have increased the risk of cell detachment yet again. 674 
Therefore, to keep the number of wash steps in the staining procedure low (i.e. two 675 
washes), it was decided to add venom and dye simultaneously, thus eliminating the 676 
wash step between dye and venom addition.    677 
 678 
Figure 3:  Two brightfield images (magnification 10x) showing leakage of venom to the neighbouring well. On 679 
the left is the control well (20 μL MQ-water) and on the right is a neighbouring well with C. fleckeri venom (20 680 
μL at 10 μg/mL). Nematocysts (circled in red) were present in both the control and the venom wells, suggesting 681 
there was leakage across wells.  682 
 683 
Consequently, the staining procedure was altered as follows:  684 
Step 1: Wash 685 
Step 2: Venom (or control) and dye addition  686 
Step 3: Wash 687 
Step 4: Chamber removal 688 
 689 
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 With this modified staining procedure, upon visual inspection of the controls, only 690 
approximately 10 % of the cells detached in total during the two wash steps. However, 691 
the wells containing the venom showed significant cell detachment (data not shown), 692 
suggesting the venom concentration was too high and needed to be adjusted (see section 693 
3.3).  694 
 695 
2.3.1.3. Venom concentration 696 
 697 
C. fleckeri venom can cause rapid cell death and detachment [7,8]; cell death and detachment 698 
occurring in under 20 minutes would have hindered the feasibility of the experiments as this is 699 
approximately the period required from the time point of envenomation to the time of 700 
microscopic analysis. Therefore, a concentration had to be identified that would cause enough 701 
damage to the cell to see the effects under the microscope without resulting in complete cell 702 
detachment from the surface of the chamber slides.  703 
 704 
Seven concentrations (10-fold dilutions) between 285 µg/mL and 0.285 ng/mL were tested, 705 
following the experimental procedure established above and using the same fluorescent dye 706 
(nuclear stain Hoechst 33342). Visual inspection under the fluorescence microscope showed 707 
that the venom concentrations did not appear to display a typical dose-response-like effect on 708 
the cells (Figure 4). For example, there appeared to be more cell detachment at a concentration 709 
of 2.85 ng/mL (Figure 4F) than at 2850 ng/mL (Figure 4C). Secondly, in most replicates, this 710 
cell detachment resulted in large cell-less patches as well as clusters of floating cells which 711 
hindered clarity and focus during imaging; rendering the replicates unusable. While no images 712 
were taken of the unusable chambers, the lack of camera focus can be seen in nearly all the 713 
images (Figure 4A-G), including the Milli-Q-water-control (Figure 4H). Thirdly, each venom 714 
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chamber had a great level of variability within itself, i.e. in one area of the chamber, imaging 715 
was easily feasible while in another area of the same chamber cells were completely detached 716 
and lumped up on the edge of the chamber and/or images would appear blurry or completely 717 
out of focus.  718 
 719 
Overall, it was difficult to systematically photograph the same section in each chamber across 720 
all samples. In addition, it was not feasible to have 7 samples in triplicates (1 replicate being 1 721 
chamber slide with 8 chambers/wells) and triplicates of the control; the time required between 722 
the removal of the chamber housing and the capturing of the image was too extensive. Finding 723 
a usable area in a chamber and adjusting the focus to that area, often required up to 10 min; 724 
leading to fading of the fluorescent dye within that chamber, as well as in neighboring 725 
chambers. Figure 4A-H shows one image of the stained cells for each concentration.  726 
 727 
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 728 
Figure 4: Imaging of the effect of different C. fleckeri venom concentrations on human cardiomyctes at a 20x 729 
magnification (scale bar: 200 μm) with a Zeiss Axio Imager M1 microscope (Carl Zeiss AG, Germany) and the 730 
Nuance Multispectral Imaging System FX (Perkin Elmer, Inc., USA). The cells were stained with the nuclear 731 
stain Hoechst 33342. Venom concentrations are indicated on each image (images A-G).  The negative control 732 
with no venom added is shown in image H. 733 
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2.3.1.4. Fluorescence microscopy imaging of envenomed cells 734 
 735 
Due to the complications encountered during the preliminary experiments, it was decided not 736 
to continue with the project to its full extent.  Initially, it was anticipated to have three 737 
replicates, i.e. three chamber slides per dye, with four control wells and four venom wells per 738 
slide. However, since handling a single chamber slide was already logistically challenging, it 739 
was decided instead to only use one chamber slide per dye. While a single chamber slide per 740 
dye lacks statistical significance, it was concluded that it would provide enough insight to 741 
determine whether it was worth pursuing the development of an alternative experimental 742 
design and method using these fluorescent dyes (i.e. flow cytometry).   743 
 744 
To analyze if fluorescent staining had the potential to reveal some of the effects of C. fleckeri 745 
venom, four different dyes were tested following the method developed in section 2.3.2. Four 746 
wells were incubated with a venom concentration of 0.1 μg/mL and the remaining four wells 747 
were used for the MQ-control. The dyes used for this experiment were Hoechst 33342 (nuclear 748 
stain), Propidium Iodide and CellMaskTM Deep Red (membrane integrity stains) as well as 749 
MitoTrackerTM Deep Red (mitochondrial stain). 750 
 751 
2.3.1.4.1. Cell nucleus  752 
 753 
To analyse the effect of C. fleckeri venom on the cardiac nuclear morphology, cells were 754 
incubated with the cell permeant nuclear stain Hoechst 33342 for a period of 10 minutes. 755 
Microscopic analysis showed that the nuclei from the envenomed cells appeared rounder and 756 
some also appeared smaller compared to the nuclei from the control cells (Figure 5). 757 
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 758 
 759 
2.3.1.4.2. Cell membrane integrity 760 
 761 
To assess the integrity of the cardiac cell membrane after C. fleckeri envenomation, two 762 
experiments were conducted. First, to assess changes in cell membrane permeability, cells were 763 
incubated for 10 minutes with the non-permeant nuclear counterstain propidium iodide in 764 
Figure 5: Imaging of the nuclear morphology of cardiomyocytes after C. fleckeri venom administration at a 200x 
magnification (scale bar 200 μm) with a Zeiss Axio Imager M1 microscope (Carl Zeiss AG, Germany) and the 
Nuance Multispectral Imaging System FX (Perkin Elmer, Inc., USA). Cells were incubated for 10 minutes with 
the nuclear stain Hoechst 33342 (5 μg/mL) and 0.1 μg/mL of venom (or MQ-water control). (A) Envenomed 
cells appeared to have a smaller nucleus than (B) the control cells.   
A 
B 
200 μm 
200 μm 
Venom 
Control 
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combination with Hoechst 33342. The characteristic red fluorescence of the non-permeant 765 
propidium iodide counterstain was present in the nuclei of several of the envenomed cells, 766 
suggesting damage to the cell wall, whereas the control cells appeared to have intact 767 
membranes as only the characteristic blue fluorescence from the cell-permeant Hoechst 33342 768 
stain was detectable during the fluorescence microscopy imaging (Figure 6).  769 
In a second experiment, to assess changes in the cell membrane morphology, the cells were 770 
incubated for 10 minutes with CellMaskTM Deep Red, a cell membrane stain. The resulting 771 
images showed that compared to the control, cells incubated with venom had undergone 772 
morphological changes as they appeared narrower and the cell membranes appeared 773 
filamentous (Figure 7). The cellular organization appeared altered as well; in the control wells, 774 
the cells appeared to be organized in a parallel pattern, whereas in the treated wells showed 775 
disorganized clusters of cells, which is likely associated to the loss of adherence of the cells. 776 
 777 
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 778 
Figure 6: Imaging of the cell membrane integrity after C. fleckerienvenomation at a 200x magnification with a 
Zeiss Axio Imager M1 microscope (Carl Zeiss AG, Germany) and the Nuance Multispectral Imaging System FX 
(Perkin Elmer, Inc., USA). Cells were incubated for 10 minutes with 0.1 μg/mL venom (or MQ-water) along 
with the nuclear stains Hoechst 33342 (5 μg/mL) and Propidium Iodide (5 μM). The non-permeant Propidium 
Iodide counterstained the envenomed cells (A), suggesting loss of membrane integrity, but not but the control 
cells which emitted only the blue fluorescent signal from the cell-permeant Hoechst stain (B).   
B 
A 
200 μm 
200 μm 
Venom  
Control 
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 779 
 780 
 781 
 782 
Figure 7: Imaging of the cell morphology after C. fleckeri envenomation at a 630x magnification with 
a Zeiss Axio Imager M1 microscope (Carl Zeiss AG, Germany) and the Nuance Multispectral 
Imaging System FX (Perkin Elmer, Inc., USA). Cells were incubated for 10 minutes with 0.1 μg/mL 
C.fleckeri venom (or MQ-control) and CellMask DeepRed. The envenomed cells (A) compared to 
the control cells (B) exhibited a loss of the typical heart cell morphology. The membranes of the 
envenomed cells appear filamentous and disintegrated as opposed to the control cells.  
A 
50 μm 
50 μm 
Venom 
Control 
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2.3.1.4.3. Mitochondrial membrane potential 783 
 784 
To assess the changes in mitochondrial activity during envenomation, the cells were incubated 785 
with the MitoTrackerTM Deep Red dye for 10 minutes. Changes in mitochondrial membrane 786 
potential results in a proportional intensity fluorescent signal from the MitoTracker dye. The 787 
cells in the control well appeared to be mostly evenly stained (Figure 8). By contrast, the cells 788 
exposed to the venom showed variation in fluorescent signal intensity, with some cells showing 789 
a bright fluorescent signal and some cells only showing weak fluorescence. Furthermore, the 790 
mitochondria also appeared to concentrate around the nucleus, as opposed to being evenly 791 
distributed in the control.  792 
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 793 
 794 
Figure 8: Imaging of the cardiomyocyte mitochondrial membrane potential at a 630x magnification with a Zeiss 
Axio Imager M1 microscope (Carl Zeiss AG, Germany) and the Nuance Multispectral Imaging System FX 
(Perkin Elmer, Inc., USA). Cells were incubated for 10 minutes with 0.1 μg/mL C.fleckeri venom (or MQ-
control) and MitoTracker Red. The image of the envenomed cells (A) shows variable fluorescent signals, as 
opposed to the more evenly distributed signals of the control cells (B). Increase in fluorescent signal indicates 
an increase of mitochondrial membrane potential and activity.   
A 
50 μm 
50 μm 
Venom 
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2.3.2. Flow cytometry  795 
 796 
2.3.2.1 Venom concentration and venom incubation time 797 
 798 
Different venom concentrations (80, 8 and 0.8 ng/mL) and venom incubation times (2, 10 and 799 
30 minutes) were tested to identify a concentration and time that would allow for the detection 800 
of a decrease and increase (left- and rightwards shift, respectively) in fluorescent signal on the 801 
fluorescence signal intensity histograms generated in the flow cytometry analysis software BD 802 
FACSDiva. With 2 minutes of incubation, only 80 ng/mL could be clearly differentiated from 803 
the control, whereas concentrations of 8 and 0.8 ng/mL did not seem to affect the cells (Figure 804 
9A). With 10 and 30 minutes of incubation all three concentrations had an effect on the 805 
cardiomyocytes, indicated by the dose-dependent rightwards shift of the fluorescent signal 806 
trace on the histograms (Figure 9B and 9C). Concentrations that allowed for a left- and 807 
rightward shift were 8 and 0.8 ng/mL at both 10 and 30 minutes, and thus it was decided they 808 
were suitable, at either of the two mentioned incubation periods, for the following experiments. 809 
While for the latter incubation periods, 80 ng/mL resulted in fluorescent signal intensities that 810 
were shifted too far right to allow for further right shift within the sensitivity tolerances of the 811 
flow cytometer, this concentration was also used for the following experiments. 30 minutes 812 
was chosen as incubation period, as it allowed for more experiment preparation time than 10 813 
or 2 minutes and was, thus, logistically favourable. In summary, for all following experiments, 814 
cells were incubated for 30 minutes with all three tested concentrations, to ensure the recording 815 
of concentration-dependent effects.  816 
 817 
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 818 
Figure 9: Fluorescent signal intensity histograms of incubation time and concentration dependent effects of C. 819 
fleckeri venom on Propidium Iodide (PI)-stained cardiomyocytes. The x-axis represents the dye intensity and y-820 
axis represents the percentage of cells of the maximum cell count. The incubation periods are indicated above 821 
each graph and the concentrations are listed on the legend. 822 
 823 
 824 
 825 
 826 
 827 
A 
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2.3.2.2. Nuclear and mitochondrial stain 828 
 829 
To assess whether C. fleckeri venom had a quantifiable effect on the cardiomyocyte nucleus 830 
and/or mitochondria, cells were exposed for 30 minutes to concentrations of 80 ng/mL, 8 831 
ng/mL and 0.8 ng/mL. C. fleckeri venom did not induce a significant change in the intensity of 832 
the fluorescence of the nuclei compared to the control, despite an observable concentration-833 
dependent increase of the peak height in the fluorescent signal intensity histograms (Figure 834 
10). Cardiomyocyte mitochondria were significantly affected by concentrations of 80 ng/mL, 835 
showing a significant (p < 0.001, FDfn, Dfd = 16.533,8) decrease in geographical mean of the 836 
intensity of the fluorescent signal (i.e. leftward shift) compared to the control (Figure 11). 837 
Similar to the Hoechst experiments, at 80 ng/mL the cells appear dead (decrease in forward 838 
scatter). The other two concentrations did not elicit an observable effect and the data is 839 
summarised in Figure 11C.  840 
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Figure 10: Nuclear dye (Hoechst 33342) experiments: Cell density charts (left) and fluorescent signal intensity 842 
histograms (right) for nucleus-stained cardiomyocytes exposed to (A) no (control), (B) 0.8 ng/mL, (C) 80 ng/mL) 843 
C. fleckeri venom. The x- and the y- axis for the cell density charts indicated the forward and the sideward scatter, 844 
respectively, of each counted cell, with a legend provided in panel (C). The x- and the y-axis for the intensity 845 
histograms represent the cell count and the intensity of the fluorescent signal, respectively. The circled data in 846 
panel (A) represents a healthy population of cardiomyocytes. The cells exposed to 80 ng/mL venom display a 847 
decreased forward scatter compared to the control, suggesting that these cells have died. The data for 8 ng/mL C. 848 
fleckeri  venom is not shown as, similar to 0.8 ng/mL, it did not differ significantly from the control.  849 
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 850 
Figure 11: MitoTracker experiments. Panel (A) and (B) show the data density charts (left) and the fluorescent 851 
signal intensity histograms (right) for the control as well as cardiomyocytes exposed to the highest concentration 852 
of venom (80 ng/mL). The other concentrations are not shown as they did not differ from the control. The circled 853 
data in panel (A) represents a healthy population of cardiomyocytes. Panel (C) shows the geographic mean of the 854 
fluorescent signal intensity (y-axis) for each of the tested samples (x-axis). Statistical significance with p < 0.05 855 
is indicated by *. 80 ng/mL induced a significant decrease in the intensity of the fluorescent signal from the 856 
mitochondria compared to the control as well as an increase in dead cells (reduced forward scatter). 857 
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2.4. Discussion 858 
 859 
2.4.1. Effect of C. fleckeri venom on cellular components of the cardiomyocyte 860 
 861 
This study presents a fluorescence microscopy imaging assay to visualise and a flow cytometry 862 
assay to quantify the effects of C. fleckeri venom on different cellular components of the 863 
cardiomyocyte. Two of the three types of cellular components assessed in this study, the 864 
nucleus and the cell membrane, exhibited distinct morphological changes after C. fleckeri 865 
administration. The morphological changes of the cell membrane were quantified by flow 866 
cytometry, but the changes to the nuclei were not quantifiable with the present method. Further, 867 
the cellular distribution of the mitochondria was altered upon administration of venom, which 868 
was accompanied by a significant decrease in the geographical mean of the fluorescent signal 869 
intensity for the highest concentration tested. Albeit the lack of statistical robustness of the 870 
fluorescence microscopy experiments due to only testing one chamber slide per dye, the results, 871 
discussed in detail below, provide some context for the effects of C.fleckeri venom on 872 
cardiomyocytes. 873 
 874 
The C. fleckeri envenomed cardiomyocytes displayed a reduced nuclear size. Many of the 875 
nuclei of the envenomed cells analysed by fluorescence microscopy appeared to “condense”; 876 
apart from becoming smaller in size, their shape also appeared rounder, similar to the nuclear 877 
condensation seen in apoptotic cells [e.g. 11]. The flow cytometry analyses could not quantify 878 
this observation; it is possible that this “condensation” does not affect the dye binding 879 
mechanism and is therefore not quantifiable in this manner. Hoechst binds to the minor grove 880 
in double-stranded DNA [20], thus the lack of effect in the flow cytometry assay suggests that 881 
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C. fleckeri venom does not degrade DNA into single strands nor does it alter the DNA content 882 
of the cells, at the concentrations tested.  883 
 884 
C. fleckeri venom caused loss of plasma membrane integrity and loss of adherent properties 885 
compared to the control cells. During the fluorescence microscopy imaging most of the 886 
envenomed cells detached, floating in the suspension, while many of the still adhering cells 887 
appeared filamentous and narrower than the control. The plasma membranes of the envenomed 888 
cardiomyocytes became permeable to propidium iodide, indicating the loss of membrane 889 
integrity. C. fleckeri venom can create pores the size of approximately 50 nm in diameter [21], 890 
thus it is not clear if the propidium iodide entered the cells through the pores or whether the 891 
membranes ruptured as a result of mechanical cell death, such as necrosis. 892 
 893 
C. fleckeri venom also appeared to alter the activity of cardiomyocyte mitochondria. The 894 
microscopic analysis showed that the mitochondrial dye had a distinctly different distribution 895 
in the envenomed cells than in the control cells. In the control cells, the MitoTracker dye was 896 
evenly distributed throughout the cardiomyocyte, while in the envenomed cells the dye 897 
appeared to aggregate around the nucleus. The flow cytometry experiments showed a 898 
significant decrease in the fluorescent signal intensity emitted from the mitochondria of cells 899 
exposed to the highest venom concentration, but not for the other concentrations. It is not clear 900 
if this loss of fluorescence is the secondary result of an increased number of dead cells (and 901 
therefore dead mitochondria) or the direct result of decreased mitochondrial functioning. The 902 
MitoTracker dye is cell permeant and works by binding to thiol-reactive chloromethyl moieties 903 
in, and then being metabolised by, the mitochondria (InvitrogenTM, USA). Therefore, in dead 904 
cells, this dye does not work adequately and a loss of fluorescence, as observed here, is to be 905 
expected. In terms of the aggregation of the mitochondrial dye observed during the microscopic 906 
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study, this could be the secondary result of the altered cell shape of the envenomed 907 
cardiomyoctyes. However, as mentioned above, the envenomed cardiomyocytes appeared 908 
narrower and filamentous in shape (compared to the control), while the mitochondrial dye 909 
aggregated in a rounded pattern around the nucleus.  910 
 911 
2.4.2 Limitations of this study 912 
 913 
The fluorescence microscopy imaging assay developed here posed several challenges and 914 
limitations relating to the preparation of the slides and the analysis of the data. A key factor for 915 
the success of this assay is the adherence of the cardiomyocytes to the chamber slides. 916 
Adequate adherence is necessary to prevent cells from being flushed away during the 917 
preparation of the slides and to ensure even distribution of the cells on the slides to enable 918 
systematic analysis with fluorescence microscopy. To counteract the problem of lack of 919 
adherence, the LabTek II Chamber slides that were initially used were replaced with LabTek 920 
CC2 coated chamber slides. This alleviated the problem to a degree, likely because the CC2 921 
coating was developed to mimic the polystyrene surface of tissue culture flasks, as opposed to 922 
the standard glass surface of the LabTek II slides. However, as soon as venom was added to 923 
the cardiomyocytes, they started to detach regardless of the CC2 coating. This resulted in 924 
problems of repeatability of the experiments. Generally, during fluorescence microscopy 925 
imaging experiments a set number of defined areas are selected for analysis, and those areas 926 
are systematically analysed on each slide, or in the present case, in each chamber. Here this 927 
type of systematic analysis was not possible, as most of the cells detached and floated away, 928 
resulting in large cell-less patches. Further, detached cells were floating above patches of 929 
attached cells, hindering the achievement of adequate focus and thus resulting in extensive 930 
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delays in finding a photographable area. This further hindered systematic analysis through the 931 
dyes fading due to prolonged exposure of the cells to the fluorescence lasers. 932 
 933 
While the flow cytometry experiments were suitable in terms of logistics, repeatability and 934 
statistical robustness, the experimental questions, i.e. whether or not the venom reduces the 935 
size of the nucleus or alters mitochondrial activity, could not be quantified adequately. Perhaps, 936 
a more extensive analysis that includes the analysis of different nuclear dyes or, for example, 937 
mitochondrial depressants, could provide more insight into the mechanism of C. fleckeri 938 
venom. 939 
 940 
Lastly, alternative imaging methods such as automated cell imagers could be explored for the 941 
visualisation of C. fleckeri venom effects. Automated cell imagers have similar features to 942 
fluorescence microscopes, without requiring the expertise of the latter. In addition to being 943 
more user-friendly, automated cell imagers can be used for qualitative and high-throughput 944 
quantitative analyses which would potentially alleviate the problems of statistical robustness 945 
encountered in this chapter.  946 
 947 
2.4.3. Conclusions 948 
 949 
While the presented data did not answer the questions originally posed in regard to C. fleckeri 950 
venom, repeated exposure of the cardiomyocytes to the venom resulted in three consistently 951 
recurring effects: cell detachment, nuclear condensation, loss of membrane integrity. C. 952 
fleckeri venom induced cell detachment of adherent cells, such as cardiomyocytes or skeletal 953 
myocytes, is a common observation and therefore myocyte adherence has often been used as a 954 
measure of cell viability [e.g. 8,9,22]. Yet, cell death as such has not been analysed. Currently 955 
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there is no evidence for the type of cardiomyocyte death induced by C. fleckeri venom, i.e. 956 
apoptosis, necrosis or other. Necrosis of the skin has been observed in envenomation victims 957 
[23], however, not in cardiac myocytes. In the present microscopic analysis, the cell walls of 958 
the envenomed cardiomyocytes were ruptured, indicating a mechanical cell death such as 959 
necrosis. On the other hand, it has previously been shown that detachment of adherent cells 960 
can lead to a programmed cell death, such as apoptosis [24]. This is supported by the 961 
“condensation” of the nuclei, which is commonly observed in apoptotic cells. Given the 962 
complexity of C. fleckeri venom, it is possible that both types of cell death (i.e. mechanical or 963 
apoptotic or similar) are induced by different toxins in the venom. Further research, perhaps 964 
with apoptotic indicators such as Annexin V or Caspase 3, could help clarify the type(s) of cell 965 
death (i.e. mechanical or programmed) induced by C. fleckeri venom. 966 
 967 
 968 
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CHAPTER 3 1038 
Characterisation of cardiotoxic protein 1039 
fractions in C. fleckeri venom 1040 
 54 
3.1. Introduction 1041 
 1042 
Chironex fleckeri is a large chirodropid Australian box jellyfish, with highly potent venom.  C. 1043 
fleckeri human envenomation causes agonising pain, local dermonecrosis and a variety of 1044 
cardiovascular symptoms that may result in cardiac arrest within minutes if the sting area is 1045 
significant [e.g. 1,2,3]. There is no empirical evidence for effective treatment, which is, in part, 1046 
related to the lack of knowledge on C. fleckeri venom components and their clinically relevant 1047 
bioactivities. Identifying and characterising the key venom components that lead to the rapid 1048 
onset of the envenomation symptoms, is essential to improve emergency care of envenomation 1049 
victims.  1050 
 1051 
C. fleckeri venom is composed of a complex mixture of protein toxins of which only some 1052 
induce cardiotoxic effects in human cells [4]. Purification of the venom with size-exclusion 1053 
chromatography resulted in seven main peaks, of which only one peak showed cardiotoxicity 1054 
in vertebrates [4]. Within this peak, two fractions, termed CTF-α and CTF-β, appear to act 1055 
synergistically to elicit toxicity on heart cells; CTF-α triggers a rapid but short-term metabolism 1056 
inhibition while CTF-β toxicity is two-fold slower but causes permanent damage [5]. The 1057 
synergistic nature of these fractions is potentially the reason for the effects observed on the 1058 
heart rate of fish exposed to C. fleckeri venom [6]. Initially, only stroke volume gradually 1059 
declines by approximately 50 % until sudden cardiac arrest occurs [6]. However, CTF-α and 1060 
CTF-β are only partially purified fractions of the venom and the components present have not 1061 
been identified. 1062 
 1063 
Transcriptomic and proteomic analyses have revealed that C. fleckeri venom contains a number 1064 
of proteins that are unique to cnidarians. These venom proteins display substantial sequence 1065 
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homology with toxins from the related cubozoans Carybdea alata, Carybdea rastoni and 1066 
Chironex yamaguchii [7]. Based on sequence alignment these cnidarian specific venom 1067 
proteins have been phylogenetically grouped into Type-1 and Type 2-toxins [8]. Type 1 toxins 1068 
include the highly cardiotoxic and haemolytic proteins CfTX-1 and CfTX-2 [9], whereas Type 1069 
2 toxins include the potently haemolytic proteins CfTX-A, CfTX-B and CfTX-Bt [8]. These 1070 
toxins are thought to act via pore-formation [8].  1071 
 1072 
Based on the bioactivity reported for C. fleckeri toxins [5,8], it appears likely that the 1073 
cardiotoxic fractions CTF-α and CTF-β are composed of Type-1 toxins. However, the masses 1074 
of these fractions can only be roughly deduced from the FPLC-standards used in that study [5] 1075 
and appear to be around 75-85 kDa for CTF-a and 35-45 kDa for CTF-β. Though, it is possible 1076 
that the molecular mass in CTF-a is the result of dimerization of CfTX-1 or -2 (approx. 43 kDa 1077 
and 45 kDa, respectively) [8,9]. To determine the precise composition and toxin masses of the 1078 
CTF-α and CTF-β fractions, further purification and mass spectrometry studies are required.  1079 
 1080 
Rationalising the bioactivity of C. fleckeri venom in terms of clinical symptoms has not been 1081 
straightforward. It appears likely that the cardiotoxic activity of C. fleckeri venom induces a 1082 
cardiovascular collapse that results in a fatal cardiac arrest [10-12]. For instance, mice injected 1083 
with partially purified cardiotoxic and haemolytic CfTX-1 and -2 toxins suffered from a rapid 1084 
cardiovascular collapse whereas mice injected with the haemolytic toxins CfTX-A and -B 1085 
suffered less pronounced cardiovascular effects [8]. However, while C. fleckeri venom is 1086 
potently haemolytic to laboratory animals [13] and human erythrocytes [14], haemolysis is 1087 
often discounted because it has not been reported in human victims [1,8,13-15]. There are very 1088 
few publicly available clinical or post-mortem reports on box jellyfish envenomations, and 1089 
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therefore, it is not clear whether haemolysis is not a clinical symptom or whether there is simply 1090 
a general lack of available clinical reports.   1091 
 1092 
Alternatively, laboratory animals such as mice, are known to display responses to certain drugs 1093 
or toxins that are distinct from humans [16] and this could account for the apparent differences 1094 
in haemolytic activity in mice and humans. For example, human beta cells are resistant to 1095 
concentrations of sodium nitroprusside, streptozotocin and alloxan that significantly reduce the 1096 
viability of rat and mouse beta cells [17]. Another example is that the anti-ulcer drug 1097 
Omeprazole, induces CYP1A2 (hemoprotein from the cytochrome P450 oxidase system) 1098 
expression in the liver of humans [18], but not mice [19]. Thus, while murine models play an 1099 
imperative role in many experimental research studies, differences between mice and humans 1100 
must be taken into account [20]. 1101 
 1102 
Here we conducted a mass spectrometric analysis of the toxic fractions CTF-α and -β, and -γ, 1103 
from size exclusion chromatography of C. fleckeri venom to identify the key components. 1104 
CTF-γ was included as a comparative fraction because it previously showed very little 1105 
cardiotoxicity and was thought to be composed of smaller sized proteins [5] than CfTX-1 and 1106 
-2. We analysed the effects of these fractions and crude C. fleckeri venom on human 1107 
cardiomyocytes and human fibroblasts, and on human and mouse erythrocytes to assess the 1108 
presence of species-specific differences. In an attempt to shed more clarity on the mechanism 1109 
by which cardiomyocyte death is induced, we also conducted an apoptosis assay. The results 1110 
of this study will be useful in directing future research studies towards the identification of the 1111 
mechanisms of action involved in C. fleckeri envenomation and consequently better treatment 1112 
methods. 1113 
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3.2. Methods  1114 
 1115 
3.2.1. Venom collection and extraction 1116 
 1117 
Large (bell size approx. 30 cm) adult C. fleckeri specimens were collected from Weipa, QLD 1118 
in December 2015. Nematocysts for venom extraction were collected following the method of 1119 
Bloom et al. [21]. In brief, tentacles were removed from the animal and placed in saltwater 1120 
buckets, where they were left for 3 days and shaken several times per day to promote autolysis 1121 
of the nematocysts from the tentacles. To remove the tentacles, the solution was passed through 1122 
a sieve and subsequently lyophilised and stored at -80 °C until required for venom extraction. 1123 
 1124 
Venom extraction was carried out following the method of Carrette and Seymour [22]. In short, 1125 
a layer of 0.5 mL of lyophilised nematocysts, followed by a 0.25 mL layer of glass beads was 1126 
filled into 1.5 mL screw-cap microcentrifuge tubes. The tubes were topped off with Milli-Q-1127 
water (MQ-water) and shaken in a mini-bead-beater; 10x for 2 min with 5 min cooling breaks 1128 
in an ice-slurry. The samples were then centrifuged at 20 000 g for 45 sec to separate ruptured 1129 
nematocyst debris (sinking to the bottom of the tube) from the venom proteins (remaining in 1130 
the supernatant). The supernatant was then collected, passed through a 0.45 μm filter (to further 1131 
remove debris), lyophilised and stored at -80 oC.  1132 
 1133 
3.2.2. Venom fractionation 1134 
 1135 
3.2.2.1. Sample preparation for venom fractionation 1136 
 1137 
Lyophilised venom was suspended in approximately 0.5 mL of MQ to obtain a highly 1138 
concentrated venom solution of approximately 10 mg/mL. The venom was then passed through 1139 
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a 0.22 μm filter to remove further debris from the sample and prevent damage to the protein 1140 
separation instrument.  1141 
3.2.2.2. Size exclusion chromatography (SEC) 1142 
 1143 
 C. fleckeri venom (350 µL) was loop-loaded and fractionated with the use of a SuperdexTM 1144 
200 Increase 10/300 GL Column (SD200, GE healthcare), equilibrated at 4 °C with phosphate 1145 
buffered saline as running buffer (1 x PBS, i.e. 137 mM NaCl, 10 mM Na2HPO4, 1.8 mM 1146 
KH2PO4, 2.7 mM KCl, pH 7.4), in a Fast Protein Liquid Chromatography (FPLC) AKTA 1147 
system (GE healthcare). The eluent was measured at 280 nm, producing a venom profile and 1148 
was thereby separated into size-specific (range: 600 kDa - 10 kDa) fractions of 0.5 mL. The 1149 
fractions equivalent to the fractions previously termed CTF-α, -β and –γ, were collected from 1150 
the wells B1 and B2, B7 and B8 as well as C1 and C2, respectively, as described in [5]. This 1151 
resulted in a total volume of 1 mL for each of the three fractions. Protein concentration 1152 
estimates from the FPLC software UNICORN (ÄKTATM, GE healthcare) were verified by 1153 
BRADFORD assay and protein concentrations were standardized across samples. 1154 
 1155 
3.2.3. Characterisation of CTF-α, -β and -γ 1156 
 1157 
3.2.3.1. Sample preparation for mass spectrometric analysis 1158 
 1159 
The concentration of the fractions (CTF-α, -β and -γ) was determined from the FPLC and a 1160 
separate spectrophotometric analysis at 280 nm. The samples were then lyophilised. 50μg of 1161 
each lyophilised sample was reduced and alkylated and then trypsin digested. Briefly, each 1162 
sample was resuspended in 240 μL of 50 mM triethylammonium bicarbonate (TEAB) and 1163 
reduced by adding 0.5 M of dithiothreitol (DTT) to a final concentration of 20 mM and 1164 
incubated at 50°C for 30 min. The samples were then alkylated by adding 0.5 M iodoacetamide 1165 
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(IAA) to a final concentration of 50 mM at RT for 30 min in the dark, the reaction was then 1166 
quenched by adding more DTT to a final concentration of 50 mM. 1167 
To concentrate the samples, 30 kDa ultra-4 filtration units (Millipore, Merck KGaA) were 1168 
washed with 1 mL of 50 mM TEAB at 4,000 x g for 10 min and then the individual samples 1169 
were loaded onto their respective filtration units and concentrated at 4,000 x g for 15 min. A 1170 
buffer exchange was performed twice by adding 500 μL of 50 mM TEAB on each of the 1171 
filtration units and centrifugated at 4,000 x g for 15 min each time. The concentrated samples 1172 
in 50 mM TEAB (approximatively 50 μL) were then collected from the filtration units and 1173 
transferred into individual Eppendorf tubes.  1174 
Next the samples were trypsin-digested by adding 3 μg of trypsin to each sample and incubated 1175 
at 37 °C overnight. The next day the digestion reaction was stopped by adding a 10 % 1176 
trifluoroacetic acid (TFA) solution to the samples to reach a final concentration of 0.1 %. The 1177 
samples were then lyophilised. 1178 
Subsequently, the samples were resuspended in 50 μL of 0.1 % TFA and then desalted using 1179 
the Zip-Tip® C18 pipette tips (Merck KGaA, Darmstadt, Germany) according to 1180 
manufacturer’s protocol with the following modifications. The tips were washed and 1181 
conditioned with 80 % acetonitrile (ACN), 0.1 % TFA then 0.1 % TFA in LC-MS grade water. 1182 
Peptides were then bound to the tips and subsequently eluted with 80 % ACN, 0.1 % TFA and 1183 
lyophilised before LC-MS analysis. 1184 
 1185 
3.2.3.2. Mass spectrometric analysis 1186 
 1187 
The tryptic fragments from the in-solution digestion were resuspended in 50 μL of 0.1 % formic 1188 
acid (FA) in LC-MS grade water and were separated by an Eksigent nanoLC 415 system (AB 1189 
Sciex) using a 15 cm long Eksigent column (C18-CL particle size 3 μm, 120 Å, 75 μm ID) 1190 
(AB Sciex) and a linear gradient of 3-40 % solvent B for 60 min followed by 60-80 % solvent 1191 
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B in 5 min. A pre-concentration step (10 min) was performed employing an Eksigent Trap-1192 
column (C18-CL, 3 μm, 120 Å, 350 μm x 0.5 mm) before commencement of the gradient. A 1193 
flow rate of 300 nL/min was used for all experiments. The mobile phase consisted of solvent 1194 
A (0.1 % formic acid [aq]) and solvent B (99.9 % acetonitrile/ 0.1 % formic acid [aq]). Eluates 1195 
from the RP-HPLC column were directly introduced into the PicoView ESI ionisation source 1196 
of a TripleTOF 6600 MS/MS System (AB Sciex) operated in positive ion electrospray mode 1197 
at a voltage of 2400 V. All analyses were performed using Information Dependent Acquisition. 1198 
AnalystTF 1.7.1 (Applied Biosystems) was used for data analysis. Briefly, the acquisition 1199 
protocol consisted of the use of an Enhanced Mass Spectrum scan with 15 seconds exclusion 1200 
time and 100 ppm mass tolerance. A cycle time of 1800 ms was used to acquire full scan 1201 
TOFMS data over the mass range 400–1250 m/z with 250 ms of accumulation and product ion 1202 
scans using rolling collision energy for 50 ms over the mass range of 100–1500 m/z for up to 1203 
30 of the most abundant ions with a relative intensity above 150 and a charge state of +2 − +5. 1204 
Full product ion spectra for each of the selected precursors were then used for subsequent 1205 
database searches. 1206 
 1207 
3.2.3.3 Peptides sequences and protein identification 1208 
 1209 
The different datasets were searched for peptide sequences and protein identifications using 1210 
the ProteinPilot software 5.0.1 (AB Sciex) against three databases: 1211 
1) A database generated from C. fleckeri transcripts (Dr. D. Brinkman’s transcripts assembled 1212 
by M.Sc. J. Portiquet, personal communication M.Sc. J. Potriquet (20,562 proteins). 1213 
2) A database generated from Carukia barnesi (Dr. D. Brinkman’s transcripts assembled by 1214 
M.Sc. J. Portiquet, personal communication M.Sc. J. Potriquet) transcriptome (1,426 proteins) 1215 
for the sake of possible homology matches. 1216 
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3) An unreviewed Toxin database generated by compiling proteins from UniProtKB database 1217 
with the “Toxins” annotation consisting of 26,142 proteins. 1218 
 1219 
All searches were conducted employing the following search parameters: trypsin as digestion 1220 
enzyme, precursor ion mass tolerance ± 0.05 Da, fragment ion tolerance ± 0.1 Da, 1221 
Iodoacetamide with other Cys mods possible for Cystein alkylation and ID focus set on 1222 
Biological modifications and FDR analysis was enabled. 1223 
Peptides and proteins identified with less than 1 % global FDR and more than 99 % confidence 1224 
were considered and the top identified proteins with a minimum of 2 unique peptides were 1225 
considered in our dataset comparison. Protein hits were order by the semi-quantitative 1226 
“peptide-hit” method [23, 24] to provide some perspective of their relative abundance.  1227 
 1228 
3.2.4. Cell culture and xCELLigence assay 1229 
 1230 
Human fibroblasts (1BR.3.GN cell line – European cell collection) and cardiodmyocytes 1231 
(ScienCell, Inc.) were cultured following the manufacturers guideline in 5 mL RPMI media 1232 
(Gibco) with 10 % Foetal Bovine Serum and Cardiac Myocyte Medium (ScienCell, Inc), 1233 
respectively, at 37 °C and 5 % CO2 in 25 cm2 monolayer flasks. The cells were seeded and 1234 
incubated in 96-E-well plates at approximately 3000 cells in 150 μL media per well for 24 h at 1235 
37 °C and 5 % CO2 to allow the cells to attach to the bottom of the wells before treatment was 1236 
applied. Cell adherence to the bottom of the plate, i.e. the cell index, a measure of cell viability 1237 
was monitored using xCELLigence single plate (SP) system and the Real Time Cell Assay 1238 
(RTCA) software. The IC50, i.e. the concentration at which 50 % of the cells die, 10 min post-1239 
venom addition, was used as a measure of venom toxicity. This time period was chosen to 1240 
allow for comparison with previously published studies. 1241 
 1242 
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 1243 
 1244 
3.2.5. Haemolytic activity 1245 
 1246 
To assess haemolytic activity, crude venom as well as the FPLC fractions CTF-α, CTF-β and 1247 
CTF-γ were tested. These fractions were chosen because there already is cardio- and 1248 
myotoxicity data available in the literature for comparison. The haemolysis test followed the 1249 
protocol of the quantitative spectrophotometric assay used by Brinkman et al., 2014 [8] for 1250 
consistency. In brief, heparinised human (ethics approval number H6838) and mouse blood 1251 
(donation from the Loukas group, AITHM) was centrifuged (2000x g, slowest deceleration 1252 
setting, 4 °C, 10 min), and the supernatant was discarded. The sedimented red blood cells 1253 
(RBC) were washed by resuspending them in cold, sterile PBS (4 °C, pH 7.8) followed by 1254 
centrifugation (2000x g, slowest deceleration setting, 4 °C, 10 min). This procedure was 1255 
repeated until the absorbance (540 nm) of the supernatant was 0.2 or less (approximately 5 1256 
times). The RBCs were diluted in PBS (4 °C, pH 7.8) to a 1 % concentration and added to a 1257 
96-well plate (300 μL / well, i.e. approximately 1.6 x 107 cells/ well). Seven dilutions of each 1258 
venom sample were then added to the plate in triplicates, as well as triplicates of a negative 1259 
(PBS) and of a positive control (1 % TritonTM x-100, Sigma-Aldrich, now Merck KGaA). The 1260 
samples were incubated for 30 min at 37 °C and afterwards centrifuged at 3000x g (slowest 1261 
deceleration setting, 4 °C, 10 min). The supernatant was transferred to a flat-bottom 96-well 1262 
plate to measure the absorbance (540 nm) of the released haemoglobin. Haemolysis results 1263 
were plotted as relative percentages from the positive (100 % lysis) and the negative (0 % lysis) 1264 
control. The graphs were created in Prism 7 (GraphPad, Inc.). 1265 
  1266 
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3.2.6. Dual apoptosis assay 1267 
 1268 
To test if C. fleckeri venom induces apoptosis in cardiomyocytes, cells were analysed by flow 1269 
cytometry with the NucView® 488 (caspase-3 detection) and CF®640R (phosphatidylserine 1270 
detection through annexin-V binding) Dual Apoptosis Assay Kit for Life Cells (Biotium, Inc.).  1271 
Cardiomyocytes were counted to prepare 200 μL solutions of 106 cells/mL and then exposed 1272 
for 30 min to two concentrations (20 and 100 ng/mL) of crude C. fleckeri venom as well as of 1273 
CTF-α, -β and -γ. Milli-Q water was used as negative control. Each sample was prepared in 1274 
triplicates. After incubation, the cells were centrifuged at 150 g for 5 min at room temperature, 1275 
the supernatant was decanted, and the resulting cell pellets were resuspended in 200 μL 1x 1276 
annexin-V binding buffer. Each sample was then incubated in the dark for 30 min with 5 μL 1277 
of 0.2 mM NucView® 488 Caspase-3 substrate stock solution (resulting in 5 μM final 1278 
concentrations) and 5 μL of CF®640R annexin-V stock solution (no concentration given). 1279 
Further, two additional triplicate samples incubated with venom (20 and 100 ng/mL) were 1280 
stained for 10 min with Propidium Iodide only (permeant to dead cells; InvitrogenTM, Thermo 1281 
Fisher Scientific) to compare the number of dead cells to the number of apoptotic cells. After 1282 
incubation, 400 μL 1x annexin-V binding buffer was added to each tube and the fluorescence 1283 
was measured in FITC (excitation/emission 485/515 nm), Cy®5 (excitation/emission 642/662) 1284 
an PE (excitation/emission 493/636 nm) channels on a BD FACSCanto II (BD Biosciences) 1285 
with the BD FACSDiva software (BD Biosciences). Statistical analysis (MANOVA and 1286 
ANOVA with Tukey multiple comparison of means) of the geometric means of the fluorescent 1287 
signal intensities and graph generation was done in Diva, R (R Foundation) and Prism 7 1288 
(GraphPad Software Inc.).  1289 
  1290 
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3.3. Results 1291 
 1292 
3.3.1 Identification of major proteins in CTF-α, CTF-β and CTF-γ 1293 
 1294 
C. fleckeri venom was fractionated as previously reported [5] using the same methodology and 1295 
conditions (Figure 1). To identify the major venom proteins in the fractions CTF-α, CTF-β and 1296 
CTF-γ, each fraction was analysed by mass spectrometry and the results were matched against 1297 
three databases (C. fleckeri, C. barnesi,and an unreviewed toxins database). Overall, the Type 1298 
I C. fleckeri toxins CfTX-1 and CfTX-2 were both present in all three fractions. The Type II 1299 
C. fleckeri toxins CfTX- A and -B were both present in CTF-β and CTF-γ, but toxin CfTX-A 1300 
was not present in fraction CTF-α. The two top hits in each fraction were: CfTX-1 and CfTX-1301 
2 for CTF-α; CaTX-A (Carybdea alata) and CfTX-A for CTF-β; CrTX-A (Carybdea rastoni) 1302 
and CfTX-A for CTF-γ. The top five venom protein hits all came from the C. fleckeri database 1303 
and are given in Table 1, including the sequence coverage at 95 % confidence and the number 1304 
of unique peptides identified at 95 % confidence. All three CTFs contained all toxins listed in 1305 
Table 1 (CfTX-1 and -2, CfTX-A and -B, CaTX-A, CrTX-A and CqTX-A (Chiropsalmus 1306 
yamaguchii)), albeit some toxins not making the top five hit list of each fraction. The data 1307 
presented here are only from the C. fleckeri database as the other databases did not result in 1308 
any higher-ranking hits. 1309 
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 1310 
Figure 1: Size-exclusion chromatogram of C. fleckeri venom. The x-axis represents the elution volume in mL 1311 
and the y-axis is a measure of the intensity of the 280 nm absorbance in mAU. CTF-α, CTF-β and CTF-γ are 1312 
indicated within Peak 2 and are each composed of two 0.5 mL fractions.    1313 
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Table 1: Top five predicted protein hits for CTF-α, CTF-β and CTF-γ*.  1314 
*The hits were ranked by the number of unique peptides (at 95 % confidence). Note, the number of unique 1315 
peptides is a semiquantitative method to determine relative protein abundances only [23,24]. The size of each 1316 
protein is lowercased once after the first appearance of that protein.  ~ indicates approximate molecular weights 1317 
due to potential posttranslational modifications. The percentage of sequence coverage was predicted at 95 % 1318 
confidence.  1319 
Sample Top Hits Species 
Unique peptides 
(95 %) 
% sequence 
coverage (95 %) 
CTF-α 
CfTX-1 (~ 43 kDa) C. fleckeri  207 81.99 
CfTX-2 (~ 45 kDa) C. fleckeri  180 78.62 
CaTX-A (43 kDa) C. alata 32 53.78 
CfTX-B (~ 42 kDa) C.fleckeri 30 63.77 
CqTX-A (44 kDa) C. yamaguchii 27 77.66 
CTF- β 
CaTX-A C. alata 412 71.40 
CfTX-A (~ 40 kDa)  C. fleckeri  409 66.74 
CfTX-B C. fleckeri  397 75.27 
CfTX-2 C. fleckeri  100 78.55 
CfTX-1 C. fleckeri  91 77.64 
CTF- γ 
CrTX-A (43 kDa) C. rastoni 168 66.16 
CfTX-A C. fleckeri  89 64.1 
CfTX-B C. fleckeri  68 70.93 
CaTX-A C. alata 61 70.63 
CfTX-2 C. fleckeri 51 70.33 
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3.3.2. Realtime cell assay of human fibroblasts and cardiomyocytes 1320 
 1321 
Human fibroblasts and cardiomyocytes were treated with several concentrations of C. fleckeri 1322 
venom and the three fractions CTF-α, CTF-β and CTF-γ, to test if the venom or the fractions 1323 
had a more pronounced effect on either cell line. Only CTF-γ had a significantly higher effect 1324 
on cardiomyocytes than on fibroblasts with IC50 concentrations of 0.38 μg/mL (95 % CI: 0.26-1325 
0.68 μg/mL) and 2.03 μg/mL (95 % CI: 1.55-2.65 μg/mL), respectively (Figure 2D, Figure 3 1326 
and Table 2). The effects of the other samples did not differ significantly between cell lines 1327 
and resulted in similar dose-response curves (Figure 2A, 2B, 2C, 2 and Table 2). C. fleckeri 1328 
venom was 114 times as toxic as the least toxic CTF-α fraction with IC50 concentrations on 1329 
fibroblasts of 0.34 μg/mL (95 % CI: 0.24-0.47 μg/mL) and 38 μg/mL (95 % CI: 22.26-473.12 1330 
μg/mL), respectively (See table 3 for detailed statistics). However, CTF-α displayed such low 1331 
toxicity that the calculation of the IC50 calculation is not reliable; this is reflected in the very 1332 
large 95 % CI. There were no significant differences between the IC50 concentrations of C. 1333 
fleckeri venom, CTF-β and CTF-γ on cardiomyocytes; the IC50 for CTF-α could not be 1334 
determined because it did not induce sufficient toxicity at 10 minutes of envenomation (Table 1335 
3).  1336 
 1337 
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 1338 
Figure 2: Dose-response curves of (A) C. fleckeri venom, (B) CTF-α, (C) CTF-β and (D) CTF-γ on 1339 
cardiomyocytes and fibroblasts. The x-axis shows the concentration [ng/mL] and the y-axis represents the 1340 
percentage of cell survival 10 minutes post envenomation. 50 % survival is marked by the horizontal dotted line. 1341 
Fibroblasts are represented by a continuous line with full circles and cardiomyocytes by a dotted line with clear 1342 
diamonds.  Error bars (standard deviation) are indicated for each data point. Some error bars were smaller than 1343 
the symbols. All four samples induced a concentration dependent response in both cell lines; cell survival is 1344 
decreasing with increasing sample concentrations.  1345 
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 1346 
Figure 3: IC50 concentrations of C. fleckeri venom, CTF-α, CTF-β and CTF-γ for fibroblasts (white) and 1347 
cardiomyocytes (solid red). The x-axis represents the different samples and the y-axis the IC50 concentrations 1348 
[μg/mL]. The y-axis is represented on a logarithmic scale due to the large differences in sample potency.  The 1349 
error bars represent the standard deviation.1350 
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Table 2: Statistical comparison of IC50 concentrations between fibroblasts and cardiomyocytes for C. fleckeri 1351 
venom, CTF-α, CTF-β and CTF-γ.  1352 
95 % CI indicates the 95 % confidence interval of the calculated IC50 concentrations. Statistical output is given as 1353 
p-value and F-statistic including the degrees of freedom. Significant p-values are highlighted in red. # Unreliable 1354 
calculation due to the extremely low toxicity of CTF-α (None of the tested concentrations resulted in 50 % lysis.) 1355 
 1356 
 Fibroblasts Cardiomyocytes Cell-line comparison 
Sample 
IC50 
[μg/mL] 
95 % CI 
[μg/mL] 
IC50 
[μg/mL] 
95 % CI 
[μg/mL] 
p-value 
F (DFn, 
DFd) 
fold-
change 
C. 
fleckeri 
venom 
0.34 
0.24-
0.47 
0.34 
0.15-
0.85 
0.9982 
5.18 x 
10-6 
(1,38) 
n/a 
CTF-α 38.79 
22.26-
473.12 
~12.6# 
n/a 
(very 
wide) 
n/a n/a n/a 
CTF-β 0.59 0.5-0.69 0.61 
0.35-
1.12 
0.8586 
0.03219 
(1,38) 
n/a 
CTF-γ 2.03 
1.55-
2.65 
0.38 
0.26-
0.81 
< 0.0001 
29.01 
(1,38) 
5.3 
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Table 3: Statistical comparison of IC50 concentrations between samples for fibroblast and cardiomyocytes.  1357 
 Fibroblasts Cardiomyocytes 
Compared samples p-value F (DFn, DFd) p-value F (DFn, DFd) 
C. fleckeri venom vs. CTF-
α 
< 0.0001 347.4 (1,38) n/a n/a 
C. fleckeri venom vs. CTF-
β 
< 0.0022 10.8 (1,38) 0.2453 1.4 (1, 36) 
C. fleckeri venom vs. CTF-
γ 
< 0.0001 66.8 (1.38) 0.8204 0.1 (1, 38) 
CTF-α vs. CTF-β < 0.0001 550.0 (1,38) n/a n/a 
CTF-α vs. CTF-γ < 0.0001 153.3 (1,38) n/a n/a 
CTF-β vs. CTF-γ < 0.0001 58.5 (1,38) 0.2478 1.4 (1, 36) 
95 % CI indicates the 95 % confidence interval of the calculated IC50 concentrations. Statistical output is given as 1358 
p-value and F-statistic including the degrees of freedom. Significant below 0.05 p-values are highlighted in red. 1359 
 1360 
3.3.3. Haemolytic activity 1361 
 1362 
The haemolytic activity of C. fleckeri venom, CTF-α, CTF-β and CTF-γ was tested on human 1363 
and mouse erythrocytes to determine if there were differences in sensitivity between the two 1364 
species. All the samples were more lytic to mouse than to human erythrocytes (Figures 4 and 1365 
5). The 50 % haemolytic activity (HU50) concentrations for mouse erythrocytes were 1366 
significantly lower than those for humans for C. fleckeri venom (~ 47 times), CTF-α (~ 37 1367 
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times) and CTF-γ (~ 5.5 times) than for human erythrocytes; the HU50 for CTF-β on mouse 1368 
blood could not be reliably calculated, as all the concentrations tested induced approximately 1369 
100 % haemolysis (Figure 5 and Table 4). The most haemolytic fraction for both human and 1370 
mouse erythrocytes, was CTF-β (and C. fleckeri venom) and the least haemolytic fraction was 1371 
CTF-α (Figure 5, Table 4 and 5).  1372 
 1373 
 1374 
Figure 4: Dose-response curves of (A) C. fleckeri venom, (B) CTF-α, (C) CTF-β and (D) CTF-γ on human and 1375 
mouse erythrocytes. The x-axis shows the concentration [ng/mL] and the y-axis represents the percentage of 1376 
haemolysis. 50 % haemolysis is marked by the horizontal dotted line. Human erythrocytes are represented by a 1377 
continuous line with full circles and mouse erythrocytes by a dotted line with clear diamonds. The error bars 1378 
represent the standard deviation. All four samples induced a concentration dependent response in both cell lines; 1379 
haemolysis is increasing with sample concentrations. 1380 
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 1381 
Figure 5: HU50 concentrations of C. fleckeri venom, CTF-α, CTF-β and CTF-γ for human (solid blue) and mouse 1382 
(white) erythrocytes. The x-axis represents the different samples and the y-axis the concentration [μg/mL] at 1383 
which 50 % of the erythrocytes undergo haemolysis (HU50). The y-axis is represented on a logarithmic scale due 1384 
to the large differences in sample potency. The error bars represent the standard deviation. The mouse erythrocyte 1385 
IC50 for CTF-β was too low to be reliably calculated, as all tested concentrations induced approximately 100 % 1386 
haemolysis. 1387 
 1388 
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Table 4: Statistical comparison of HU50 concentrations between human and mouse erythrocytes for C.fleckeri 1389 
venom, CTF-α, CTF-β and CTF-γ .  1390 
95 % CI indicates the 95 % confidence interval of the calculated HU50 concentrations. Statistical output is given 1391 
as p-value and F-statistic including the degrees of freedom. Significant p-values are highlighted in red. † Unreliable 1392 
calculation due to the extremely high toxicity of CTF-β (Each of the tested concentration resulted in approximately 1393 
100 % lysis.) 1394 
Sample 
Human Mouse Comparison of cell lines 
HU50 
[μg/mL] 
95 % CI 
[μg/mL] 
HU50 
[μg/mL] 
95 % CI 
[μg/mL] 
p-value 
F (DFn, 
DFd) 
fold- 
change 
C. 
fleckeri  
venom 
0.059 
0.026-
0.133 
0.001 
0.001-
0.003 
< 0.0001 
45.0 
(1,37) 
47 
CTF-α 1.862 
1.353-
2.682 
50.1 
0.033-
0.076 
< 0.0001 
197.4 
(1,37) 
37 
CTF-β 0.024 
0.009-
0.049 
0.001† n/a n/a n/a n/a 
CTF-γ 0.065 
0.043-
0.098 
0.012 
0.011-
0.013 
< 0.0001 
80.6 
(1,38) 
5.5 
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Table 5: Statistical comparison of HU50 concentrations between samples for human and mouse erythrocytes.  1395 
Compared samples 
Human Mouse 
p-value F (DFn, DFd) p-value F (DFn, DFd) 
C. fleckeri venom vs. CTF-
α 
< 0.0001 74.2 (1, 38) < 0.0001 85.4 (1, 36) 
C. fleckeri venom vs. CTF-
β 
0.0913 3.0 (1, 38) 0.7 0.2 (1, 37) 
C. fleckeri venom vs. CTF-
γ 
0.8324 0.1 (1, 38) < 0.0001 66.0 (1, 38) 
CTF-α vs. CTF-β < 0.0001 168.1 (1, 38) n/a n/a 
CTF-α vs. CTF-γ < 0.0001 158.3 (1, 38) < 0.0001 n/a 
CTF-β vs. CTF-γ 0.0129 6.8 (1,38) n/a n/a 
95 % CI indicates the 95 % confidence interval of the calculated IC50 concentrations. Statistical output is given as 1396 
p-value and F-statistic including the degrees of freedom. Significant p-values are highlighted in red. 1397 
 1398 
3.3.4. Apoptosis assay 1399 
 1400 
Cardiomyocytes were treated with two concentrations of C. fleckeri, CTF-α, CTF-β and CTF-1401 
γ and analysed by flow cytometry to test for the presence of the apoptotic indicators caspase-3 1402 
and phosphatidylserine (PS). During early apoptosis pro-caspase-3 is activated to caspase-3, 1403 
thus detection of caspase-3 is an indicator for early apoptosis [25]. During the mid/late stages 1404 
of apoptosis, PS (a cytosolic component of the cell membrane) is expressed on the outer cell 1405 
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membrane, allowing detection of apoptosis with the non-cell permeant annexin-V stain, which 1406 
has a high affinity for PS [26]. 1407 
The fluorescent signal intensity was tested for normality using a quantile plot (data not shown) 1408 
and revealed an approximate normal distribution (the sample size was a limiting factor). The 1409 
two dependent variables (annexin-V and caspase-3) were also at least somewhat correlated 1410 
(data not shown) and therefore a MANOVA was conducted to test if there was a significant 1411 
difference between the fluorescent signals for annexin-V and caspase-3, followed by an 1412 
ANOVA including a Tukey’s comparison of the mean values for each tested venom type.  1413 
 1414 
The results indicate significant differences in fluorescent signal expression for annexin-V (PS-1415 
binding) and caspase-3 among the treatment groups (C. fleckeri , CTF-α, CTF-β and CTF-γ) 1416 
for both concentrations (p < 0.0001, FDfn, Dfd = 11.01118, 40). In detail, at 20 ng/mL there was a 1417 
significant overall difference (i.e. cumulative fluorescent signal intensity of annexin-V and 1418 
caspase-3 dye) between treatment groups (p = 0.03404 FDfn, Dfd = 2.70298, 20) and accordingly 1419 
a significant difference in annexin-V (p < 0.001, FDf = 12.8934) and caspase-3 fluorescent signal 1420 
intensity (p < 0.0001, FDf = 721.014). Similarly, the treatment groups differed significantly at 1421 
100 ng/mL in the overall fluorescent signal intensity (p = 0.03404 FDfn, Dfd = 2.70298, 20) as well 1422 
as for the signal for annexin-V (p < 0.001, FDf = 12.944) and caspase-3 (p < 0.0001, FDf = 1304) 1423 
(Figure 6-9). Unfractionated C. fleckeri venom did not differ from the control for either 1424 
concentration (Figure 6). At the lower concentration, only CTF-γ induced a significant increase 1425 
in the annexin-V and caspase-3 fluorescent signal intensity, more so for the latter than for the 1426 
former (Figure 9). At 100 ng/mL, compared to the control, CTF-α induced a significant 1427 
increase in the annexin-V signal intensity, but no caspase-3 was detected (Figure 7). CTF-β 1428 
(Figure 8) had the reverse effect to CTF-α and did not induce an increase in the annexin-V 1429 
signal intensity but appeared to induce caspase-3 activation. Of all tested treatments, CTF-γ 1430 
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induced the most significant increase in the annexin-V signal intensity and (more so) in 1431 
caspase-3 activation in cardiomyocytes at both concentrations (Figure 10 and 11). The results 1432 
of the Tukey’s multiple comparison test are given in Table 6 and 7.  1433 
 1434 
 1435 
Figure 6: C. fleckeri venom effect on cardiomyocytes exhibiting fluorescent signal intensities of caspase-3 and 1436 
annexin-V at 2 concentrations: 20 ng/mL (blue) and 100 ng/mL (black). The control is indicated in red. Healthy 1437 
cells exhibit low fluorescent signal intensities for both dyes of up to approximately 103. Apoptotic cells are in the 1438 
fluorescent signal intensity range of 104 – 105. Both cell populations (healthy and apoptotic) are present for all 1439 
treatments (including the control), with the no increase in the number of apoptotic cells compared to the control 1440 
when exposed to 20 ng/mL or 100 ng/mL of C. fleckeri venom. 1441 
 1442 
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 1443 
 1444 
Figure 7: CTF-α effect on cardiomyocytes exhibiting fluorescent signal intensities of caspase-3 and annexin-V 1445 
(binds to PS) at 2 concentrations: 20 ng/mL (blue) and 100 ng/mL (black). The control is indicated in red. Healthy 1446 
cells exhibit low fluorescent signal intensities for both dyes of up to approximately 103. Apoptotic cells are in the 1447 
fluorescent signal intensity range of 104 – 105. Both cell populations (healthy and apoptotic) are present for all 1448 
treatments (including the control), with the number of apoptotic cells increasing compared to the control when 1449 
exposed to 100 ng/mL, but not 20 ng/mL, of CTF-α. 1450 
 79 
1451 
Figure 8: CTF-β effect on cardiomyocytes exhibiting fluorescent signal intensities of caspase-3 and annexin-V at 1452 
2 concentrations: 20 ng/mL (blue) and 100 ng/mL (black). The control is indicated in red. Healthy cells exhibit 1453 
low fluorescent signal intensities for both dyes of up to approximately 103. Apoptotic cells are in the fluorescent 1454 
signal intensity range of 104 – 105. Both cell populations (healthy and apoptotic) are present for all treatments 1455 
(including the control), with the number of apoptotic cells increasing compared to the control when exposed to 1456 
100 ng/mL, but not 20 ng/mL, of CTF-β. 1457 
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1458 
Figure 9: CTF-γ effect on cardiomyocytes exhibiting fluorescent signal intensities of caspase-3 and annexin-V at 1459 
2 concentrations: 20 ng/mL (blue) and 100 ng/mL (black). The control is indicated in red. Healthy cells exhibit 1460 
low fluorescent signal intensities for both dyes of up to approximately 103. Apoptotic cells are in the fluorescent 1461 
signal intensity range of 104 – 105. Both cell populations (healthy and apoptotic) are present for all treatments 1462 
(including the control), with the number of apoptotic cells increasing compared to the control when exposed to 1463 
either concentration of CTF-γ. 1464 
 1465 
 1466 
 81 
 1467 
Figure 10: Geometric means of fluorescent signal intensities from the annexin-V (black) and caspase-3 (red) 1468 
fluorescent signals in cardiomyocytes exposed to 20 ng/mL of C. fleckeri venom (CFV), CTF-α, CTF-β, CTF-γ 1469 
and a control (100 % Milli-Q-water). The y-axis represents the geometric means and the x-axis represents the 1470 
different venom compounds. The error bars represent the standard deviation. Significant increases in fluorescent 1471 
signal intensity compared to the control are represented by ** (p < 0.01) and **** (p < 0.0001). 1472 
 1473 
 1474 
 1475 
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 1476 
Figure 11: Geometric means of fluorescent signal intensities from the annexin-V (black) and caspase-3 (red) 1477 
fluorescent signals in cardiomyocytes exposed to 100 ng/mL of C. fleckeri venom (CFV), CTF-α, CTF-β, CTF-γ 1478 
and a control (100 % Milli-Q-water). The y-axis represents the geometric means and the x-axis represents the 1479 
different venom compounds. The error bars represent the standard deviation. Significant increases in fluorescent 1480 
signal intensity compared to the control are represented by * (p < 0.05), ** (p < 0.01), *** (p < 0.001) and **** 1481 
(p < 0.0001). 1482 
 1483 
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Table 6: Summary of p-values (9 5 % CI) for Tukey’s comparison of means of annexin-V and caspase-3 1484 
fluorescent signal intensities induced by 20 ng/ mL of C. fleckeri, CTF-α, CTF-β and CTF-γ. 1485 
Compared 
samples 
(20 ng/ mL) 
Annexin-V Caspase-3 
p-value Difference 95 % CI p-value Difference 95 % CI 
Control - C. 
fleckeri 
venom 
0.9999 -7.3 
-596.0 –  
581.3 
0.9609 -144.0 
-862.8 –  
574.8  
Control - 
CTF-α 
 
0.9997 
-32.3 
-621.0 –  
556.3 
0.9492 -155.3 
-874.2 –  
563.5 
Control - 
CTF-β 
0.9942 70.0 
-518.7 –  
658.7 
0.996 -77.7 
-796.5 – 
641.2 
Control - 
CTF-γ 
0.0016 -1,004.3 
-1,593.9 – 
-415.7 
<0.0001 -9,366.3 
-10,085.2 – 
-8,647.5 
C. fleckeri 
venom - 
CTF-α 
0.9999 -25.0 
-613.7 –  
563.7 
< 1 -11.3 
-730.2 – 
707.5 
C. fleckeri 
venom - 
CTF-β 
0.9916 77.3 
-511.3 – 
666.0 
0.9978 66.3 
-652.5 – 
785.2 
C. fleckeri 
venom - 
CTF-γ 
0.0017 -997.0 
-1,585.6 – 
-408.4 
< 0.0001 -9,222.3 
-9,941.2 – 
-8,503.5 
CTF-α - 
CTF-β 
0.9763 102.3 
-486.3 –  
691.0 
 
0.996 77.7 
-641.2 – 
796.5 
CTF-α - 
CTF-γ 
0.0020 -972.0 
-1,560.7 –  
-383.4  
< 0.0001 -9,211.0 
-9,929.8 – 
-8,492.2 
CTF-β - 
CTF-γ 
0.001 -1074.3 
-1,663.0 – 
-485.7 
< 0.0001 -9,288.7 
-10,007.5 – 
-8,569.8 
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Table 7: Summary of p-values (95 % CI) for Tukey’s comparison of means of annexin-V and caspase-3 1487 
fluorescent signal intensities induced by 100 ng/ mL of C. fleckeri, CTF-α, CTF-β and CTF-γ. 1488 
Compared 
samples 
(100 ng/ 
mL) 
Annexin-V Caspase-3 
p-value difference 95 % CI p-value difference 95 % CI 
Control - C. 
fleckeri 
venom 
0.5558 -443.3 
-1,383.9 – 
497.2 
0.9423 -745.7 
-4,068.2 – 
2,576.8 
Control - 
CTF-α 
0.026 
 
-1,061.3 
-2,001.9 – 
120.8 
0.9301 -789.7 
-4,1112.2 – 
2,532.8 
Control - 
CTF-β 
0.1002 -811.7 
-1,752.2 – 
128.8 
0.0083 -4,503.7 
-7,826.2 –  
-1,181.2 
Control - 
CTF-γ 
0.0004 -1,936.0 
-2,876.5 –  
-995.5 
< 0.0001 -19,278.0 
-22,600.5 –  
-15,955.5 
C. fleckeri 
venom - 
CTF-α 
0.2678 -618.0 
-1,558.5 – 
322.5 
< 1 -44.0 
-3,366.5 – 
3,278.5 
C. fleckeri 
venom - 
CTF-β 
0.7035 -368.3 
-1,308.8 – 
572.2 
0.0256 -3,758.0 
-7,080.5 – 
-435 
C. fleckeri 
venom - 
CTF-γ 
0.0028 -1,492.7 
-2,433.2 –  
-552.1 
< 0.0001 -18,532.3 
-21,854.8 – 
-15,209.8  
CTF-α - 
CTF-β 
0.9002 249.7 
-690.9 – 
1,190.2  
0.0274 -3,714.0 
-7,036.5–  
-391.5  
CTF-α - 
CTF-γ 
0.0714 -874.7 
-690.9 –  
1,190.2 
< 0.0001 -18,488.3 
-21,810.8 –  
-15,165.8 
CTF-β - 
CTF-γ 
0.0185 -1,124.3 
-2,064.9 –  
-183.8  
< 0.0001 -14,774.3 
-18,096.8 – 
-11,451.8 
1489 
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3.4. Discussion  1490 
 1491 
The present characterisation of the fractions CTF-α, CTF-β and CTF-γ has provided further 1492 
insight into C. fleckeri venom proteins and their cytotoxic effects. CTF-α, CTF-β and CTF-γ 1493 
show a similar composition of cubozoan venom proteins with variation in abundance of these 1494 
proteins and thus varying cytotoxic effects that are induced through potentially distinct 1495 
molecular pathways.  1496 
 1497 
3.4.1. Toxin identification of CTF-α, CTF-β and CTF-γ 1498 
 1499 
The top five protein hits of the three fractions included the C. fleckeri toxins CfTX-1, CfTX-2, 1500 
CfTX-A and CfTX-B. Interestingly, they also abundantly included other cnidarian toxins, 1501 
namely CaTX-A (C. alata), CrTX-A (C. rastoni) and CqTX-A (C. yamaguchii). In fact, while 1502 
the most abundant hit for CTF-α was a C. fleckeri toxin (i.e. CfTX-1), for CTF-β it was the C. 1503 
alata toxin CaTX-A (albeit along with toxins CfTX-A and -B), and for CTF-γ it was the C. 1504 
rastoni toxin CrTX-A, each counting at least 160 unique peptides and a minimum of 66 % 1505 
sequence coverage. These matches all came from the C. fleckeri database [7], as none of the 1506 
matches from the toxins or the C. barnesi database (J. Potriquet) counted more than 20 unique 1507 
peptides (data not shown). Due to the high level of homology across cnidarian protein toxins 1508 
[7], it is not clear if the protein hits indicate the actual presence of these proteins or if the 1509 
fractions contain unidentified toxins that are highly homologous to these hits.  Without the 1510 
assembly of the transcripts into a transcriptome reference library [7] this cannot be clarified. 1511 
 1512 
Additional proteins were also predicted to be present in the fractions, for example protein 1513 
disulfide isomerase 2, which is found in many organisms; 41 unique peptides were matched 1514 
with approximately 50 % sequence coverage to this protein from the roundworm 1515 
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Caenorhabditis elegans. In cone snails, protein disulfide isomerase aids conotoxin folding 1516 
[27], thus it may be of relevance in C. fleckeri venom. However, the venom extraction method 1517 
could lead to contamination, and given that C. elegans is widely distributed in Australia, it is 1518 
not clear whether this match represents a contamination or an actual match. To avoid 1519 
misinterpretation of the relevance of such matches, the data presented here stem from a 1520 
conservative selection process.  1521 
3.4.1.1. CTF-α 1522 
 1523 
CTF-α appears to be primarily composed of the potently cardiotoxic and haemolytic proteins 1524 
CfTX-1 and CfTX-2. Despite the presence of these proteins, the IC50 of CTF-α indicated that 1525 
it was the least potent fraction tested. The IC50 concentration for CTF-α at ten minutes post 1526 
administration for human cardiomyocytes was greater than 12 μg/mL. The cardiomyocyte IC50 1527 
value (at the same time point) for CTF-α in the literature was approximately 20 times more 1528 
potent (250 ng/mL) [5]. Further, CfTX-1 and CfTX-2 are thought to be responsible for the 1529 
cardiovascular effects in vivo [8,9,28], therefore fractions containing predominantly these 1530 
toxins were expected to display higher cardiotoxicity than other fractions. It is well documented 1531 
that C. fleckeri venom, similar to other venomous animals [29], varies in toxicity depending on 1532 
the size, the geographical location and the year the animal was collected [30]. While the venom 1533 
used in the previous study [5] was collected from the same location and from similar sized 1534 
animals, it was collected from different individuals in a different year and may contribute to 1535 
weaker CTF-α toxicity as observed in the present study. 1536 
 1537 
3.4.1.2. CTF-β 1538 
 1539 
The most abundant protein in CTF-β were the C. alata toxin CaTX-A (412 unique peptides), a 1540 
43 kDa haemo- and cytolysin [31] and the C. fleckeri toxins CfTX-A and CfTX-B (409 and 1541 
397 unique peptides, respectively). CTF-β displayed the highest haemolytic activity of all the 1542 
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tested fractions, with an HU50 concentration for mice of < 0.5 ng/mL, a concentration ten times 1543 
higher than previously reported for fractions containing CfTX-A and -B [8]. CTF-β had a 1544 
cardiomyocyte IC50 value of 0.6 μg/mL, which is consistent with previous data on this fraction 1545 
[5].  1546 
 1547 
3.4.1.3. CTF-γ 1548 
 1549 
The top two hits for CTF-γ were the toxin CrTX-A from the box jellyfish C. rastoni [32] with 1550 
168 unique peptides followed by CfTX-A with 89 unique peptides. CrTX-A is a haemolysin 1551 
that has been shown to be a more potent than CaTX-A [32], the top hit in fraction CTF-β. 1552 
Although our results showed that CTF-β was more haemolytic than CTF-γ, it is likely that the 1553 
concentration of CaTX-A in CTF-β is higher than the concentration of CrTX-A in CTF-γ, 1554 
based on the number of unique peptides for those two proteins (412 and 168, respectively). 1555 
Similarly, fraction CTF-β likely also contained a higher concentration of the potently 1556 
haemolytic toxins CfTX-A and CfTX-B than CTF-γ, thus providing a logical rationale for the 1557 
greater haemolytic activity observed in CTF-β.  1558 
 1559 
3.4.1.4. Molecular weights of the CTF-toxins  1560 
 1561 
The molecular weights previously reported for CTF-α, CTF-β and CTF-γ, based on size 1562 
exclusion chromatography, are only partially consistent with the toxins identified in these 1563 
fractions. The top-five toxins hits all have molecular weights between 40-45 kDa. The fact that 1564 
the proportions of these toxins vary in the fractions, suggests that the individual toxins behave 1565 
distinctly when passing through the size-exclusion column. For example, CTF-α was estimated 1566 
at 75-85 kDa [5] and the top two hits for this fraction were CfTX-1 (~43 kDa) and CfTX-2 1567 
(~45 kDa), this suggests that CfTX-1 and/or -2 may be present in a dimerized form in the CTF-1568 
α fraction (oligomerisation of the CfTX-toxins has been previously suggested [8]).  By contrast, 1569 
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CTF-β was estimated at 35-45 kDa [5], which is consistent with all toxins in their monomeric 1570 
state. The high presence of CaTX-A (43 kDa), CfTX-A (40 kDa) and CfTX-B (42 kDa) in this 1571 
fraction, could suggest that these proteins may form predominantly monomers under the buffer 1572 
conditions used. Similarly, CTF-γ, estimated to be below 15 kDa [5], may be composed of 1573 
breakdown products of these toxins; the high presence of CrTX-A in this fraction may suggest 1574 
that, under presented conditions CrTX-A fragments, and further, that these fragments are 1575 
bioactive. More research is required to determine if the “separation” achieved by the size-1576 
exclusion chromatography of jellyfish venoms is perhaps influenced more by the 1577 
dimeric/monomeric/fragmented state of the proteins under set conditions than by the actual 1578 
molecular weight of the different jellyfish toxins. 1579 
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3.4.2. Bioactivity of C. fleckeri venom 1580 
 1581 
3.4.2.1. Lack of cardiospecificity of C. fleckeri venom 1582 
 1583 
Previous data suggested that CTF-α and CTF-β may be composed of cardiospecific toxins 1584 
because they were more toxic to human cardiomyocytes than to skeletal muscle cells [5]. The 1585 
present study highlights the importance of assessing toxicity on a range of cell lines, as there 1586 
was no indication that these two fractions were more toxic to human cardiomyocytes than to 1587 
fibroblasts. As mentioned above, only CTF-γ, previously characterised as non-cardiospecific 1588 
[5], was more toxic to the cardiomyocytes than to fibroblasts. In addition, all fractions were 1589 
potently haemolytic, indicating that although C. fleckeri venom is highly cardiotoxic, it does 1590 
not appear to be specific to cardiac cells when compared to skin derived fibroblast cells.  1591 
 1592 
3.4.2.2. Comparison of haemolytic effects in mouse and human erythrocytes 1593 
 1594 
Despite several studies showing haemolytic activity of the venom of C. fleckeri in vitro and in 1595 
vivo (i.e. laboratory animals), haemolysis has not been reported in human envenomation 1596 
victims [8,13-15]. The present HU50 comparison of human and mouse cells exposed to C. 1597 
fleckeri venom, indicates that mouse erythrocytes are significantly (47-fold) more susceptible 1598 
to the venom than human erythrocytes, with HU50 concentrations of approximately 1.2 ng/mL 1599 
and 59 ng/mL, respectively. Discrepancies between laboratory animals and humans are well 1600 
documented, and the differences in venom potencies might (at least somewhat) explain why 1601 
haemolysis is seen in some laboratory animals but not in humans. However, many studies on 1602 
C. fleckeri venom were conducted on rats [11,12] and the present results should not be 1603 
extrapolated.  1604 
 1605 
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3.4.3. Molecular pathways to cardiac cell death – Dual apoptosis assay 1606 
 1607 
The proteins present in the C. fleckeri venom fractions (CTF-α, CTF-β and CTF-γ) appear to 1608 
act via distinct molecular pathways. Analysis of apoptotic indicators caspase-3 and PS 1609 
expression (binds to annexin-V) showed that the different fractions had differing effects. The 1610 
increase of PS binding without caspase-3 activity observed for CTF-α might indicate that 1611 
CfTX-1 and CfTX-2, the most abundant proteins present, act via a pathway that is independent 1612 
of caspase-3.  There are a number of newly discovered pathways to cell death that are currently 1613 
being investigated, some of which induce apoptosis independently from caspase-3 activation, 1614 
however these pathways are not well documented yet [26,33]. Alternatively, the fluorescently 1615 
labelled annexin-V (which binds to PS), is a non-permeant dye and can only bind to PS once 1616 
it is translocated to the outer membrane. However, this dye does not distinguish between 1617 
cytoplasmic and extracellular PS, and thus may bind to cytoplasmic PS if the cell membrane is 1618 
compromised from e.g. necrosis or pore formation [34].  1619 
 1620 
By contrast, during most caspase-dependent apoptotic processes, pro-caspase-3 is activated to 1621 
caspase-3 before the translocation of PS to the surface of the cell membrane [33]. Thus, the 1622 
activation of caspase-3 without PS binding for CTF-β indicates that the cardiomyocytes were 1623 
in the early apoptotic stages, whereas the presence of both indicators for CTF-γ indicated a 1624 
mid/late stage of apoptosis.  1625 
 1626 
Interestingly, despite cell death occurring at 100 ng/mL (data not shown), C. fleckeri venom 1627 
did not induce apoptosis, suggesting that although apoptotic cell death is induced by some 1628 
toxins in C. fleckeri venom (i.e toxins in CTF-γ), it does not appear to be the primary cause of 1629 
cell death during C. fleckeri envenomation. Some toxins are able to induce both apoptosis and 1630 
necrosis, where the type of cell death depends on the concentration of the toxin [25,26]. For 1631 
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example, cobra venom cytotoxins exhibited apoptotic anticancer activity in a limited range of 1632 
toxin concentrations and at higher concentrations necrosis was observed [35]. The current 1633 
assay represents a first step into identifying the types of cell death at play during C. fleckeri 1634 
envenomation; more extensive apoptosis and necrosis assays are required to determine the 1635 
primary pathways and the biochemical factors influencing their occurrence. 1636 
 1637 
3.5. Conclusion 1638 
 1639 
In the current study, we have shown that fractions enriched for various cubozoan toxins have 1640 
distinct effects on cell lines, erythrocytes and apoptosis. Further research on these fractions is 1641 
required to determine the active constituents with more confidence. In addition, we show 1642 
distinct differences between mouse and human erythrocytes upon treatment with C. fleckeri 1643 
venom and fractions, which has implications for the interpretation of previous studies.  1644 
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CHAPTER 4 1738 
Structural characterisation of predicted helical 1739 
regions in the Chironex fleckeri CfTX-1 toxin 1740 
 96 
4.1. Introduction 1741 
 1742 
The Australian box jellyfish, Chironex fleckeri, belongs to a family of cubozoan jellyfish that 1743 
are known for their potent venoms [1-3]. In the northern half of the Australian continent, C. 1744 
fleckeri envenomations, ranging from mostly minor to occasionally life threatening, occur 1745 
frequently, particularly during October-June [4]. Envenomation symptoms include immediate 1746 
severe pain, cutaneous inflammation, cardiovascular distress and dysfunction, loss of 1747 
consciousness and potential cardiac arrest [5,6].  1748 
The venom of C. fleckeri is of particular clinical relevance as rapid cardiovascular collapse 1749 
followed by death can occur within minutes [6,7]. The majority of the venom toxins are 1750 
proteins with a variety of distinct functions. These protein toxins include CfTX-like proteins, 1751 
a variety of enzymes such as proteases and oxido-reductases, CRISP-toxins, an alpha-1752 
macroglobulin and a protease inhibitor [8]. The most abundant CfTX protein toxins in the 1753 
venom are CfTX-1 and -2 and CfTX-A and -B. Fractions with predominantly the CfTX-1/2 or 1754 
CfTX-A/B toxins both have potent hemolytic activity (HU50 £161 ng/mL), with the latter 1755 
toxins being more potent (HU50 5 ng/mL) [9-11]. By contrast, fractions with the CfTX-1/-2 1756 
toxins induce a rapid fatal cardiovascular collapse in rats, whereas fractions with CfTX-A and 1757 
-B have only minor cardiotoxic effects [9]. Phylogenetic analysis of the amino acid sequences 1758 
of these venom proteins indicates the toxins belong to two functionally and structurally distinct 1759 
subfamilies; Type I (CfTX-1 and -2) and Type II (CfTx-A and B) [9]. Thus far, the potent Type 1760 
I cardiotoxins CfTX-1 and -2 have only been found in C. fleckeri , suggesting that these 1761 
proteins are likely the cause of the rapid cardiovascular collapse observed in severe 1762 
envenomations and hence, potentially the reason why this species is considered the most 1763 
dangerous of its family [9]. 1764 
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There is no experimental structural information on C. fleckeri toxins. However, secondary 1765 
structure analysis on CfTX-1 and 2 has predicted that the first 300 amino acids are dominated 1766 
by a-helices and loop structures, including an amphiphilic a-helix in the N-terminal region 1767 
that is followed by a transmembrane spanning region, which is also predicted to be helical [11]. 1768 
Predicted amphiphilic a-helices in the N-terminal region of toxin sequences of other cubozoan 1769 
jellyfish (Chiropsalmus quadrigatus, Carybdea rastoni, Alatina alata (previously Carybdea 1770 
alata [12]), have been suggested to be associated with their hemolytic activity [13,14]. In 1771 
addition, the predicted transmembrane spanning region consists of a series of highly conserved 1772 
amino acids in CfTX-1 and -2 as well as the related jellyfish toxins CqTX-A, CrTXs and CaTX-1773 
A [11], and has also been implicated in the mechanism of action of these toxins. 1774 
Transmembrane spanning regions are commonly seen in pore-forming toxins [15,16], thus 1775 
suggesting that the cardiotoxicity of CfTX-1 and -2 might result from the transmembrane 1776 
spanning region integrating itself into the membrane of the cardiomyocytes and creating pores 1777 
in the process. This would create a rational for previously observed non-specific ion leakage 1778 
into the cardiac cell, followed by increased calcium levels. This increase has been suggested to 1779 
induce irregular contractions of the single cardiomyocyte, leading to a communal flagging of 1780 
contractions of cardiac cells overall, and thus resulting in cardiovascular collapse [17]. The 1781 
locations of the predicted amphiphilic a-helix and transmembrane spanning region in CfTX-1 1782 
are shown in Figure 1. There is no experimental evidence for the existence of the putative 1783 
structures of these two regions and therefore conclusions on the function of these regions 1784 
remain hypothetic. Experimental evidence on these putative structures is imperative to provide 1785 
a baseline for future studies directed towards developing effective treatment of C. fleckeri 1786 
envenomation but is also likely to provide insight into the development of bioactive peptides 1787 
that might have potential for the development of C. fleckeri venom derived drugs. 1788 
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a-Helices have been shown to form in isolation [reviewed in 18] and can either be derived 1789 
from larger proteins or present in small naturally occurring peptides such venom derived 1790 
peptides. The aim of the current study was to determine if regions associated with the predicted 1791 
helical regions in the CfTX-1 toxin can form well-defined structures in solution. The results of 1792 
this study provide insight into the structural architecture of CfTX-1 and provide a foundation 1793 
for future structural analysis on C. fleckeri toxins. 1794 
 1795 
Figure 1: N-terminal region of C. fleckeri toxin CfTX-1. The predicted amphiphilic α-helix and the 1796 
transmembrane spanning region (TSR1) as defined by Brinkman and Burnell [11] are indicated by a dotted and 1797 
continuous underline, respectively. The sequences of the two peptides synthesized in the current study include the 1798 
complete amphiphilic α-helix (blue) and part of the TSR1 (red), respectively. 1799 
 1800 
4.2. Materials and Methods  1801 
 1802 
4.2.1. Peptide synthesis and purification  1803 
 1804 
Peptides were synthesised by solid-phase peptide synthesis on an automated PS3™ peptide 1805 
synthesizer (Protein Technologies Inc.) using fluorenylmethyloxycarbonyl (Fmoc) chemistry 1806 
on a 0.1 mmole scale. Peptides were assembled on 2-chlorotrityl chloride resin (Auspep, 1807 
Australia). Amino acids were activated in peptide grade dimethylformamide (DMF, Auspep, 1808 
Australia) using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 1809 
(HBTU, Iris Germany). The first amino acid was coupled manually. Peptides were cleaved in 1810 
a trifluoroacetic acid (TFA)/H2O/triisopropylsilane (TIPS) (95:2.5:2.5) mixture for 2 h. After 1811 
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cleavage, the TFA was evaporated with nitrogen and the peptides were precipitated in cold 1812 
diethyl ether (4°C). The ether was removed by filtration and the precipitated peptides were 1813 
solubilised in a mixture of acetonitrile (ACN)/H2O/TFA (CfTX-122-47: 5:94.95:0.05; CfTX-173-1814 
100: 25:74.95:0.05) and then lyophilised. The resulting peptides were purified by reversed phase 1815 
high performance liquid chromatography (RP-HPLC) (Agilent 1200 Infinity series, Agilent 1816 
Technologies, Inc.) on a semi-preparative C-18 column (Jupiter 4 μm C18 Proteo 90 A° 250 1817 
mm x 10.00 mm, Penomenex, Inc.). The peptides were eluted using a 1 %/ min gradient of 1818 
solvent B (solvent A: 0.05 % TFA, solvent B: 90 % ACN, 0.05 % TFA) starting at 0 % and 25 1819 
% solvent B for CfTX-122-47 and CfTX-173-100, respectively and finishing at 90 % solvent B. 1820 
Absorbance traces of the effluent were collected at 214 and 280 nm. The purity of the eluted 1821 
peptide was verified by analytical RP-HPLC (Agilent 1260 Infinity series, Agilent 1822 
Technologies, Inc.) with a C-18 column (Eclipse Plus 3.5 μm 4.6 mm x 100 mm, Agilent 1823 
Technologies, Inc.) and the mass was analysed using MALDI mass spectrometry.   1824 
 1825 
4.2.2. NMR Spectroscopy and Structure Determination  1826 
 1827 
The purified peptides were dissolved in a mixture of 89.9%H2O:10%D2O:0.1%TFA and 69.9 1828 
% H2O:20%ACN:10%D2O:0.1%. A 600 MHz AVANCE III NMR spectrometer (Bruker, 1829 
Karlsruhe, Germany) with a cryogenically cooled probe was used to acquire two-dimensional 1830 
(2D) 1H- 1H TOCSY and 1H- 1H NOESY spectra at 303 K. 4,4-dimethyl-4-silapentane-1-1831 
sulfonic acid was used as a chemical shift reference. NMR spectra were also collected for both 1832 
peptides in 100 mM SDS 90% H2O:10%D2O. All spectra were recorded with an interscan delay 1833 
of 1 s. NOESY spectra were acquired with mixing times of 200-300 ms, and TOCSY spectra 1834 
were acquired with isotropic mixing period of 80 ms. Standard Bruker pulse sequences were 1835 
used with an excitation sculpting scheme for solvent suppression. Assignments were made 1836 
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based on the procedure described by [30]. Slowly exchanging amide protons were detected by 1837 
acquiring a series of one-dimensional and TOCSY spectra after dissolution of the peptides in 1838 
100 mM SDS in D2O.  1839 
Three-dimensional structures were determined with the program CYANA [22]. Non-intra 1840 
residue peaks in the NOESY spectra were automatically assigned and an ensemble of structures 1841 
calculated. Dihedral angle restraints derived from TALOS+ [31] were used in the structure 1842 
calculations. Hydrogen bonds predicted from preliminary structures, that were consistent with 1843 
the slowly exchanging amide protons, were subsequently included in the structure calculations. 1844 
A final ensemble of 100 structures was calculated and the 20 structures with the lowest target 1845 
functions chosen to represent the structures of CfTX-122-47 and CfTX-173-100. The structure 1846 
statistics were calculated with CYANA and MOLMOL [23].  1847 
 1848 
4.2.3. Structural predictions for CfTX-1, CfTX-122-47, CfTX-173-100 1849 
 1850 
iTASSER [24] was used to generate a three-dimensional structure model of CfTX-1. PrDOS 1851 
[25] was used to predict natively disordered regions of CfTX-1, CfTX-122-47 and CfTX-173-100. 1852 
PrDOS is a protein disorder prediction system that is based on two predictors: 1) the amino 1853 
acid sequence of the protein being analysed (implemented using support vector machine) and 1854 
2) template proteins or homologues with available structural information (implemented using 1855 
PSI-BLAST and PrDOS measure of disorder. The method was assessed by the CASP 1856 
benchmark and achieved high performance, in particular for short disordered regions.  1857 
 1858 
 1859 
 1860 
 1861 
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4.3. Results 1862 
 1863 
4.2.1. CfTX-1 peptides – design and synthesis 1864 
 1865 
The peptide design was based primarily on the predicted helical regions in CfTX-1 (Figure 1) 1866 
[11]. The length of the predicted amphipathic helix in CfTX-1 involves residues 24-33 whereas 1867 
the putative transmembrane spanning region with at least one helix, although not precisely 1868 
defined, was located within residues 68-112. An intermediate length (approximately 25 1869 
residues) was chosen for both peptides as peptides of this length are more likely to have 1870 
secondary structure than smaller peptides (for example see [19]) and are less likely to have 1871 
significant overlap in the NMR spectra, which can be present in relatively large peptides (for 1872 
example see [ 20]). The termini of the synthetic peptides were chosen based on sequence 1873 
similarity with related toxins including CfTX-2, CqTX-A, CrTXs and CaTX-1 [11]. The 1874 
sequences of the synthetic peptides, termed CfTX-122-47 and CfTX-173-100 to designate the 1875 
residue numbering for the N- and C-termini, are shown in Figure 1. Henceforth, the residue 1876 
numbers for each of the two synthetic peptides will be referred to in numerical order starting 1877 
with 1, e.g. the first residue of CfTX-122-47 will be referred to as residue 1 of CfTX-122-47.  1878 
The peptides were synthesized using Fmoc chemistry, purified using RP-HPLC and 1879 
characterized using mass spectrometry. CfTX-173-100 was significantly more hydrophobic than 1880 
CfTX-122-47 based on the retention time on RP-HPLC; 66 min (59.9 % acetonitrile - ACN) and 1881 
33.5 min (30 % ACN) on a 1 % gradient, respectively. 1882 
 1883 
 1884 
 1885 
 102 
4.2.2. Structural analysis using NMR spectroscopy 1886 
 1887 
NMR spectroscopy was used for the structural analysis of the two peptides. The one-1888 
dimensional spectra of CfTX-122-47 had limited chemical shift dispersion in the amide region.  1889 
Resonances were assigned using two-dimensional TOCSY and NOESY spectra and the 1890 
secondary shifts were calculated by subtracting random coil shifts [21] from the αH shifts. The 1891 
secondary shifts for CfTX-122-47 are close to random coil values as shown in Figure 2, 1892 
indicating that the peptide lacks structure in an aqueous environment.  1893 
CfTX-173-100 was insoluble in aqueous solution but soluble in 20 % acetonitrile. However, the 1894 
one-dimensional spectrum of CfTX-173-100 in 20 % acetonitrile showed broad peaks, indicating 1895 
that the peptide is aggregating under these conditions. Given the apparent aggregation of CfTX-1896 
173-100 and the lack of structure for CfTX-122-47, the NMR data was therefore repeated for both 1897 
peptides in the presence of deuterated sodium dodecyl sulfate (SDS) micelles. In SDS, both 1898 
peptides had enhanced chemical shift dispersion in the amide region and the secondary shifts 1899 
of CfTX-122-47 and CfTX-173-100 were consistent with helical structure based on the consecutive 1900 
negative shifts (more negative than -0.1), as shown in Figure 2.  1901 
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 1902 
Figure 2: Secondary a-H shifts of CfTX-122-47 and CfTX-173-100. (A) Secondary a-proton shifts for CfTX-1903 
122-47 in H2O (black bars) and in 100 mM SDS (grey bars with black border). Secondary shift values of CfTX-1904 
122-47 in an aqueous environment are generally within ±0.1, indicating lack of structure; whereas the values of 1905 
CfTX-122-47 in SDS are lower than -0.1ppm between residues 4 and 19 (corresponding to residues 25 and 40 in 1906 
the full-length protein), indicating an a-helical structure in this environment. (B) Secondary a-proton shifts for 1907 
CfTX-173-100 in SDS. All secondary shift values between residues 3 and 20 (corresponding to residues 75 and 1908 
92 in the full-length protein), except residue 9, 12 and 17 (corresponding to residues 81, 84 and 89 in the full-1909 
length protein) are below -0.1ppm indicating a helical structure. Residue 12 (corresponding to residue 84 in the 1910 
full-length protein) could not be assigned due to overlap with other NOEs. 1911 
 1912 
The three-dimensional structures of both peptides were determined using the program CYANA 1913 
[22]. The structures of CfTX-122-47 were determined based on 263 NOEs and 43 dihedral angle 1914 
restraints. Secondary structure analysis using MOLMOL [23] indicated that an a-helix was 1915 
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present between residues 4 to 19 (corresponding to residues 25 to 40 in the full-length protein). 1916 
The structures of CfTX-173-100 were determined based on 437 NOEs and 45 dihedral angle 1917 
restraints. Secondary structure analysis using MOLMOL indicated that an a-helix was present 1918 
between residues 3-20 (corresponding to residues 75-92 in the full-length protein). The 1919 
structural statistics for the peptides are given in Table 1 and an overlay of the 20 lowest energy 1920 
structures given in Figure 3. The greater number of NOEs for CfTX-173-100 appears to be related 1921 
to more overlap in the amide region of CfTX-122-47. A surface structure representation for both 1922 
peptides is given in Figure 4.  1923 
Table 1. Structural statistics for CfTX-122-47 and CfTX-173-100. 1924 
 
Peptide 
CfTX-122-47 CfTX-173-100 
Experimental restraints   
Interproton distance restraints 263 437 
Intraresidue, |i-j|=0  122 145 
Sequential, |i-j|=1 82 158 
Medium range, 1 <|i-j| < 5 59 134 
Dihedral-angle restraints 43 45 
R.m.s. deviations from mean coordinate structure (Å)  
Backbone atoms (indicated) 0.32 ± 0.12 (res. 4-19) 0.43 ± 0.17 (res.3-20) 
All heavy atoms (indicated) 1.48 ± 0.23 (res. 4-19) 1.06 ± 0.25 (res. 3-20) 
Backbone atoms (all) 2.19 ± 0.79 0.89 ± 0.32 
All heavy atoms (all) 3.18 ± 0.87 1.36 ± 0.32 
Ramachandran (%)   
Residues in most favoured regions 85.8 91.3 
Residues in additionally allowed regions 14.2 8.7 
 1925 
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 1926 
Figure 3: Structural analysis of CfTX-1 derived peptides. The three-dimensional structure of the 20 lowest energy 1927 
structures of (A) CfTX-122-47 and (B) CfTX-173-100 highlighting the well-defined helical region between residues 1928 
4-19 and 3-20 (corresponding to residues 25-40 and 75-92 in the full-length protein), respectively, as well as the 1929 
less defined C-terminus. (B) Cys3 (corresponding to Cys75 in the full-length protein) was substituted for an 1930 
alanine residue (Ala3) to prevent disulfide bridge formation. Asn21 and Pro22 (corresponding to Asn42 and Pro94 1931 
in the full-length protein) indicate the region of the turn in CfTX-122-47 and CfTX-173-100, respectively. The figure 1932 
was created in MOLMOL [23]. 1933 
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 1934 
Figure 4 Surface representation of CfTX-1 derived peptides. Hydrophobic residues are represented in green, polar 1935 
residues in cyan, glycine residues in grey, positively and negatively charged residues in dark blue and red, 1936 
respectively. The charge states represent expected states at physiological conditions based on generic pKa values 1937 
for glutamic acid and aspartic acid residues (~4) and lysine and arginine residues (>10). CfTX-122-47 has a cluster 1938 
of positively and negatively charged residues on one face of the molecule and a cluster of hydrophobic residues 1939 
on the other face. CfTX-173-100 shows an extended patch of hydrophobic residues. The arrow pivoting around the 1940 
axis in the top and bottom center represents the 180º turn between figure (A), (C) and (B), (D), respectively. The 1941 
figure was generated in PyMol (Schrödinger, Inc.). 1942 
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4.2.3. Structure predictions for CfTX-1 1943 
 1944 
As there is no experimental structure available for CfTX-1 we used iTASSER [24] to produce 1945 
a model to compare our peptide structures with the predicted structure of the full-length protein. 1946 
The highest-ranking protein structure is shown in Figure 5. The structure was based on the 1947 
crystal structure of an insecticidal d-endotoxin Cry8Ea1 from Bacillus thuringiensis, which has 1948 
25 % sequence identity with CfTX-1. The iTASSER score was -3.12. The first 373 residues of 1949 
the model are dominated by a-helices whereas the remaining 83 residues are a mix of helices, 1950 
coil structures, bends and b-sheets.  1951 
The regions corresponding to the peptides CfTX-122-47 and CfTX-173-100 are shown on the 1952 
model in green and red respectively. Overall, the structures of the peptides in SDS are 1953 
consistent with the iTASSER model of CfTX-1, however, the terminal regions of the peptides 1954 
differ from the model in that they are not well defined. Further, the “bend” in the helix of 1955 
CfTX-173-100 rotates the C-terminal residues into a slightly different orientation from that 1956 
present in the CfTX-1 model.  1957 
Given the lack of structure of CfTX-122-47 in aqueous solution we analyzed the propensity of 1958 
CfTX-1 to have disordered structure using the program PrDOS [25]. This analysis indicated 1959 
that the majority of the protein is structured (Figure 6), consistent with the iTASSER model. 1960 
Interestingly, there are small regions predicted to be disordered including residues 20-65 which 1961 
encompasses the sequence of CfTX-122-47. The isolated sequence of CfTX-122-47 was also 1962 
predicted to be disordered by PrDOS (Figure 6A). By contrast, CfTX-173-100 was predicted to 1963 
be structured (Figure 6B). The NMR data for CfTX-122-47 solubilized in water is consistent with 1964 
the PrDOS results, which indicated that the respective sequence is unstructured.  1965 
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 1966 
Figure 5 i-TASSER model of CfTX-1. This model represents the highest-ranking modelled protein structure. The 1967 
model indicates three multi-helical regions separated by loop structures. The location of CfTX-122-47 is shown in 1968 
green and CfTX-173-100 in red. (A) and (B) are rotated 180º with respect to each other. The figure was generated 1969 
in PyMol (Schrödinger, Inc.). 1970 
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 1971 
Figure 6. Protein disorder predictions. Residues above/below the threshold probability of 0.5 (red line) are classed 1972 
as disordered/structured with a false positive rate of 5.0 %. (A) The disorder prediction for CfTX-1, which 1973 
indicates a mostly structured protein with four disordered regions between residues 20-65 (location of CfTX-122-1974 
47), 131-132, 143-156 and 174-181. (B) This disorder prediction for CfTX-122-47 and CfTX-173-100. The former 1975 
appears to lack structure whereas the latter appears structured between residues 3-26 (corresponding to residues 1976 
75-98 in the full-length protein). The analysis was conducted with the online protein disorder prediction system 1977 
PrDOS [25]. 1978 
 1979 
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4.4. Discussion 1980 
 1981 
This study provides the first experimental data regarding the structures of peptides derived 1982 
from the putatively poreforming C. fleckeri toxin, CfTX-1. Two of the regions previously 1983 
predicted to be involved in helices [11] behave differently in aqueous solution but both form 1984 
well defined helices in the presence of SDS. Structural predictions of the full-length protein 1985 
provided some context for the experimental structures.  1986 
The region predicted to form an amphiphilic a-helix in CfTX-1 (residues 25-32) appears to be 1987 
disordered in aqueous solution based on the chemical shift analysis of CfTX-122-47. By contrast, 1988 
the chemical shift analysis in the presence of 100 mM SDS has several consecutive negative 1989 
shifts, consistent with helical structure. This helical structure was confirmed by determination 1990 
of the three-dimensional structure (Figure 2). SDS-micelles have previously been shown to 1991 
stabilise helical structures, likely because the micelles solvate the hydrophobic regions of the 1992 
peptide (for example see [26]). The helix formed in the presence of SDS has an amphiphilic 1993 
nature as one face contains mainly charged residues whereas the opposite face is significantly 1994 
more hydrophobic. The model of CFTX-1 predicted using iTasser shows that residues 22-47 1995 
are involved in a helical structure (including a turn centered at residue 33) but analysis of the 1996 
intrinsic disorder using PrDOS suggests that this region is unstructured in the full-length 1997 
protein, as well as in the isolated peptide. Our NMR results in aqueous solution are consistent 1998 
with the PrDOS results, however the propensity of the peptide to form helical structure, albeit 1999 
in the presence of a detergent, is consistent with the modelled structure and the predicted 2000 
secondary structure [11]. An experimental structure of the full-length protein is required to 2001 
answer the question of whether this region is structured in the protein or not.  2002 
CfTX-173-100 encompasses many of the residues previously predicted to be involved in a 2003 
transmembrane helix in CfTX-1 which was suggested to be involved in the putatively pore 2004 
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forming mechanism of the protein [11]. CfTX-173-100 is significantly more hydrophobic than 2005 
CfTX-122-47, is insoluble in aqueous solution and appears to aggregate in a water/acetonitrile 2006 
solution. However, in the presence of SDS the peptide is soluble, gives relatively sharp peak 2007 
in the NMR spectra, and has a well-defined helical structure for most of the peptide. Our 2008 
experimental structure of CfTX-173-100 in SDS is largely consistent with the model of CfTX-1. 2009 
Residues 73-100 in the model have predominantly helical structure with a bend region before 2010 
a proline residue. The terminal regions of the peptide are disordered, as is often present in 2011 
small, unconstrained peptides. The orientation of the bend region of CfTX-173-100 also slightly 2012 
differs from the model. Overall, our analyses on CfTX-173-100 are consistent with this region of 2013 
the protein being involved in membrane spanning [11]. Transmembrane peptides are generally 2014 
hydrophobic, aggregate in aqueous solutions and form helices under certain conditions [27], 2015 
similar to what we have observed for CfTX-173-100. Based on our structural data it is interesting 2016 
to speculate that this helical region is involved with the putative pore formation that appears to 2017 
be associated with C. fleckeri toxins [17, 28]. Transmembrane regions are commonly observed 2018 
in toxins that operate by pore formation [29]. However, further research into the structure of 2019 
C. fleckeri toxins and their mechanism is required to draw a definitive conclusion. 2020 
In summary, this study represents the first structural characterization of isolated regions of 2021 
CfTX-1. Amphiphilic helices have been predicted for the N-terminal region of several jellyfish 2022 
toxins, including CfTX-1, but the present data suggest this region does not have an intrinsic 2023 
propensity to form an a-helix in isolation. By contrast, the experimental data are consistent 2024 
with the structural predictions for the putative transmembrane spanning region. The current 2025 
study also provides information on the chemical and physical properties of these peptides, 2026 
which might facilitate the development of effective treatment and/or venom-derived drug 2027 
development.  More research into the structures and bioactivity of the full-length protein is 2028 
needed to elucidate the mode of action of C. fleckeri toxins.  2029 
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CHAPTER 5 2107 
Conclusions and Future directions 2108 
 116 
5.1. Conclusions 2109 
The analysis and characterisation of the components involved in C. fleckeri envenomation has 2110 
been a research target for many years [1-3]. This thesis has presented new insights into the 2111 
bioactivity and potential modes of actions of the venom as well as a first structural analysis of 2112 
a major C. fleckeri toxin.   2113 
 2114 
Cubozoan jellyfish envenomations are a recurring problem for bathers in tropical areas all over 2115 
the world [4-7]. These jellyfish are known for their potent cytotoxic, haemolytic and potentially 2116 
lethal toxins that are unique to the cubozoan family [8]. The toxin composition of the venoms 2117 
across many cubozoan species appears to be similar [9] and thus the research presented in this 2118 
thesis on the venom of C. fleckeri is also of relevance for these related species.  2119 
 2120 
Chapter 2 was based on the premise that severe C. fleckeri envenomations can lead to 2121 
cardiovascular collapse due to the cardiotoxic properties in the venom. The specific aim of this 2122 
chapter was to analyse the cardiotoxic effects of crude C. fleckeri venom on a cellular and, 2123 
more specifically, on an intracellular level. The expected outcomes were the visualisation of 2124 
the cell organelles and compartments affected by C. fleckeri venom with the aim of determining 2125 
their relevance in the cardiomyocyte death during C. fleckeri envenomation.  2126 
 2127 
The microscopy method used for Chapter 2 required adequate adherence of the cardiomyocyte 2128 
to the bottom of specialised cell culture slides.  Despite several attempts to improve cell 2129 
adherence, through use of specialised chamber slides and optimisation of the staining protocol, 2130 
the necessary cell adherence for a systematic evaluation of the experiments was not achieved. 2131 
However, the experiments in Chapter 2 consistently indicated three events during C. fleckeri 2132 
envenomation, 1) loss of cell adherence, 2) “condensed” nuclei and 3) loss of membrane 2133 
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integrity. Loss of cell adherence and loss of membrane integrity following C. fleckeri 2134 
envenomation have already been described, to some degree, in the literature [10-12]. By 2135 
contrast, this is the first study to report nuclear condensation in the cardiomyocyte (or any other 2136 
cell type) post C. fleckeri venom exposure. It was this nuclear condensation in combination 2137 
with the loss of adherent properties that prompted the idea to conduct an apoptosis FACS assay 2138 
in Chapter 3. The apoptosis assay was of particular interest because thus far only necrosis (of 2139 
the skin), in accordance with the loss of membrane integrity, had been reported for C. fleckeri 2140 
envenomation. However, the loss of membrane integrity in the Chapter 2 study was a 2141 
conclusion drawn from the presence of propidium iodide (non-permeant cell stain) in the 2142 
envenomed cardiomyocyte. Due to the putatively pore-forming properties of the venom, it was 2143 
not clear if the propidium iodide entered the cells through the pores or because of necrosis 2144 
induced cell membrane rupture. In an attempt to shed some light on whether the cells were 2145 
undergoing necrosis or apoptosis (as suggested by the nuclear condensation) or perhaps neither 2146 
following C. fleckeri envenomation, the apoptosis assay was carried out in Chapter 3. In 2147 
conclusion, fluorescence microscopy is not an effective technique for analysing the effects of 2148 
C. fleckeri venom on live cardiomyocytes, but indicated that apoptosis might be occurring, 2149 
which was explored using flow cytometry in Chapter 3. 2150 
 2151 
The overall objective of Chapter 3 was the characterisation of the toxins in the previously 2152 
determined bioactive fractions CTF-α, CTF-β and CTF-γ from C. fleckeri venom. The specific 2153 
aims of this chapter were 1) identifying whether or not the cardiotoxic C. fleckeri proteins 2154 
CfTX-1 and -2 were present in these fractions, 2) conducting bioactivity assays to compare the 2155 
effects of the venom and the fractions on different cell lines, 3) determining if apoptosis is a 2156 
relevant type of cell death in C. fleckeri envenomation. This chapter was expected to provide 2157 
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some of the missing links between previous proteomic and bioactivity studies on C. fleckeri 2158 
venom and to identify potential molecular pathways of the different toxins. 2159 
 2160 
All aims for chapter 3 were successfully completed and the study provided several new insights 2161 
in terms of composition, bioactivity and molecular pathways impacted by C. fleckeri venom. 2162 
The first aim, the characterization of the C. fleckeri fractions CTF-α, CTF-β and CTF-γ was 2163 
performed by using Fast Protein Liquid Chromatography (FPLC) and mass spectrometry with 2164 
a subsequent database search. The top two hits were CfTX-1 (176 unique peptides (UPs)) and 2165 
CfTX-2 (145 UPs) for CTF-α, CaTX-A (340 UPs) and CfTX-1 (78 UPs) for CTF-β and CrTX-2166 
A (169 UPs) and CaTX-A (91 UPs) for CTF-γ. CTF-α showed the least toxic activity of all the 2167 
fractions, despite the abundant presence of CfTX-1 and CfTX-2; two proteins suggested to be 2168 
highly toxic [13]. CTF-β was the most cardiotoxic and CTF-γ the most haemolytic out of the 2169 
tested fractions. The high abundance of CaTX-A in CTF-β suggests that this protein is 2170 
responsible for the cardiotoxic activity, and similarly, the high abundance of CrTX-A in CTF-2171 
γ appears to be responsible for the haemolytic activity. Interestingly, all three fractions had the 2172 
same top five database hits in differing order of abundance, all of which were proteins unique 2173 
to the phylum Cnidaria. It appeared this difference in abundance of the top five proteins was 2174 
the underlying cause for the differences observed amongst the fractions in the subsequent 2175 
bioactivity assays, suggesting that each of these toxins has a distinct mode of action. However, 2176 
the fact that the top hits were the same across fractions also suggests that the size exclusion 2177 
column used on the FPLC may not be adequate in fully separating these proteins, most likely 2178 
as a result of the similar molecular weights of the toxins. Additionally, it has been suggested 2179 
that C. fleckeri toxins may form oligomeric complexes [8], which would likely contribute to 2180 
molecular weight discrepancies and separation problems through size-exclusion. Further 2181 
separation based on hydrophobicity or cation/anion exchange chromatography might improve 2182 
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the separation, but was beyond the scope of the current study, as this study used a single 2183 
(limited) source of venom for consistency and consequently further purification was not 2184 
feasible at this stage of the project. 2185 
 2186 
The second aim of chapter 3 was to explore the bioactivity of C. fleckeri venom and the three 2187 
CTF-fractions. These bioactivity experiments were designed to answer two specific questions: 2188 
a) Does C. fleckeri venom have a higher specificity for cardiac cells than other cells? b) Is C. 2189 
fleckeri venom more toxic to murine blood than to human blood? These questions were 2190 
successfully answered by showing that neither C. fleckeri venom, CTF-α nor CTF-β had a 2191 
greater effect on cardiac cells compared to fibroblasts. Surprisingly, the CTF-γ fraction, that 2192 
was previously described as non-cardiotoxic, displayed greater toxicity in cardiomyocytes than 2193 
in fibroblasts. Further, it appears C. fleckeri venom is more toxic to murine than human 2194 
erythrocytes, which provides the first experimental explanation for the haemolytic in vivo 2195 
effects observed in mice but not in humans. The successful completion of this aim provided 2196 
essential knowledge for the experimental designs  and interpretation of future C. fleckeri venom 2197 
studies. 2198 
The third aim of chapter 3 was to investigate the molecular pathways involved in C. fleckeri 2199 
induced cardiomyocyte death using flow cytometry. The primary pathway investigated was 2200 
apoptosis by screening for the presence of the apoptotic markers caspase-3 and 2201 
phosphatidylserine (PS). The only fraction that tested positive for both caspase-3 activity and 2202 
PS-binding, was CTF-γ, indicating the cells exposed to this fraction were apoptotic. CTF-α 2203 
induced cell death appeared to act through caspase-3-independent pathways, thus not 2204 
apoptosis. In contrast, CTF-β showed caspase-3 activity but no PS-binding suggesting the 2205 
cardiomyocytes were in the early stages of apoptosis. Interestingly, C. fleckeri venom did not 2206 
indicate caspase-3 activity, or PS-binding, suggesting that the primary molecular pathway of 2207 
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C. fleckeri venom inducing cardiomyocyte death is not apoptosis at the concentrations and time 2208 
point tested. While the primary cell death mechanism of the venom remains to be fully 2209 
elucidated, the results from this chapter suggest that several cell death pathways are occurring 2210 
during C. fleckeri envenomation, likely because of the many different toxins in the venom.  2211 
There are two reasons the focus was laid on apoptosis as a cell death pathway. Firstly, the 2212 
results of chapter 2 suggested that this cell death pathway was worth investigating (e.g. nuclear 2213 
condensation) and secondly, the knowledge on other types of cell death is still emerging, and 2214 
consequently available tests are limited. Nevertheless, several new types of cell death are 2215 
currently being defined [14-16], revealing new ways of investigation as research is progressing. 2216 
 2217 
Chapter 4 focused on the structural characterization of two regions of C. fleckeri venom protein 2218 
CfTX-1 that, based on sequence analysis, were predicted to form helical structures and 2219 
suggested to be involved in membrane pore-formation during the envenomation process. The 2220 
aim of this chapter was to validate these predictions by conducting the first structural analysis 2221 
of regions of a C. fleckeri toxin.  2222 
  2223 
The structural analysis in Chapter 4 was successfully carried out with the use of nuclear 2224 
magnetic resonance spectroscopy (NMR-spectroscopy). The two predicted helical regions 2225 
were synthesised into the peptides CfTX-122-47 and CfTX-173-100. The peptides were initially 2226 
put in an aqueous solution, however CfTX-122-47 did not form a helical structure under these 2227 
conditions and CfTX-173-100 appeared to aggregate. Two alternative solvents were available for 2228 
the subsequent experiments; dimethyl sulfoxide (DMSO) and sodium dodecyl sulfate (SDS). 2229 
The advantage of using DMSO is that this solvent can be used for bioactivity studies, but it 2230 
does not provide the membrane-mimicking environment of SDS. Previous studies predicted 2231 
that the region of CfTX-1 corresponding to CfTX-173-100 was a trans-membrane-spanning 2232 
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region and thus SDS, also with its membrane-mimicking properties, was considered the more 2233 
relevant solvent for this structural analysis. The resulting structures of CfTX-122-47 and CfTX-2234 
173-100 in SDS were indeed of helical nature, and thus provided the first experimental structural 2235 
evidence towards a potentially pore-forming mode of action for CfTX-1. 2236 
 2237 
In summary, my thesis has illustrated the complexity of working with C. fleckeri venom and 2238 
has provided several links across studies in the existing literature. My thesis has also provided 2239 
a first experimental structural analysis, the results of which should facilitate future attempts of 2240 
structural characterisation of C. fleckeri (and other cnidarian) toxins.  2241 
 2242 
5.2. Future directions 2243 
Perhaps the most critical future direction is the assembly of the transcripts from the C. fleckeri 2244 
transcriptome analysis in order to create a publicly available library C. fleckeri venom proteins. 2245 
This would enable the confident identification of relevant toxins of bioactive fractions such as 2246 
the CTF’s in Chapter 3 and consequently help identify key protein toxins for the mechanism 2247 
of action of C. fleckeri venom. Further, it would perhaps be beneficial to conduct a series of 2248 
transcriptome analysis on C. fleckeri venom from different geographical locations, thereby 2249 
enabling the further description of geographical differences amongst venom samples. This 2250 
might have implications for future studies and in particular, for antivenom production.  2251 
 2252 
Another avenue that may be of benefit to explore, would be the sequencing of the C. fleckeri 2253 
genome. The application of the C. fleckeri genome would be influential in many research fields 2254 
that affect the management of this species. Phylogenetic studies could finally address the 2255 
missing links relating to the evolution of the potent toxins found in cubozoan venoms. Life 2256 
cycle studies would gain a better understanding of the different developmental stages of C. 2257 
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fleckeri and potentially provide some clues to the environmental requirements of these stages. 2258 
Currently very little is known about where C. fleckeri jellyfish are when they are not in the 2259 
medusa stage. Such information would greatly facilitate the management of the species and, 2260 
perhaps more importantly, it would open the door for captive breeding programs, which are 2261 
helpful for genetic manipulation studies on venom expression. 2262 
 2263 
Another possible direction for C. fleckeri venom studies could be the use of recombinant 2264 
protein expression systems. Protein expression systems would eliminate the need to separate 2265 
the complex C. fleckeri venom sample by chromatography. However, Dr. Diane Brinkman 2266 
attempted the expression of CfTX-1 and -2 in an Escherichia coli system during her PhD and 2267 
while the expression was completed, the yield of the recombinant proteins was too low to 2268 
conduct subsequent functional and structural studies. She also raised the issue that expressed 2269 
proteins formed insoluble inclusion bodies that would have to be solubilised and then refolded 2270 
prior their use in bioactivity studies.  2271 
 2272 
In terms of structural studies, many avenues are still to be unexplored. Chapter 4 illustrated 2273 
some of the potential challenges associated with the successful structural analysis of C. fleckeri 2274 
toxins by NMR spectroscopy, but it particularly highlighted the need for method expansion of 2275 
such studies. Perhaps NMR spectroscopy could be combined with X-ray crystallography and 2276 
de novo structure predictions. 2277 
 2278 
Finally, for the elucidation of the molecular pathways of C. fleckeri venom, SWATH-mass 2279 
spectrometry could be a method worth exploring. SWATH (Sequential Window Acquisition 2280 
of all THeoretical spectra) is a mass spectrometry method with the capacity to analyse 2281 
inherently dynamic biological processes in perturbed systems (e.g. the cell) [17]. SWATH is 2282 
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able to generate accurate, reproducible and complete data on complex protein networks [17] 2283 
by producing a permanent record of almost every single peptide fragment in the sample [18]. 2284 
Thus, SWATH is a only high-throughput method that can reliably quantify temporal changes 2285 
in protein networks. Recently, the expression of over 3600 proteins in uninfected and HIV-1 2286 
infected monocyte-derived macrophages was successfully identified and quantified, while 2287 
revealing that 420 of these proteins were severely altered upon HIV infection [17]. This HIV 2288 
study indicates that SWATH methods hold strong potential to analyse the effects of C. fleckeri 2289 
venom treatment on heart cells. Although SWATH currently requires a high level of expertise, 2290 
it is developing into an accessible pipeline for systems biology studies and is worth testing in 2291 
other biological fields such as toxicology.  2292 
 2293 
A greater understanding of the components in C. flekeri venom and their roles in the 2294 
envenomation process could ultimately lead to better treatments. Furthermore, the discovery 2295 
of novel toxins will add to the expanding library of bioactive marine toxins, which is proving 2296 
to be a valuable resource for dissecting pharmacological pathways and developing novel drug 2297 
leads.   2298 
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